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ABSTRACT
Iresine celosia L. is a traditional medicine used by the indigenous Mayan
people for a variety of ailments. It is also the sole active ingredient in the
Odyliresin™ formulation currently marketed to humans worldwide as an
antioxidant and for the promotion of prostate health. However, Odyliresin™ has
not been characterized phytochemically, or evaluated biologically for its intended
use. This work represents the first comprehensive phytochemical investigation of
the Odyliresin™ formulation botanical extract. To better understand its
constitutive phytochemistry, a tailored isolation scheme was developed, using
various chromatography resins (silica gel, LH-20), separation and purification
techniques.

In all, eleven compounds were isolated from the extract. Relevant

marker compounds were isolated and characterized using HR-MS, NMR, HPLCUV, FT-IR and CD spectroscopy. These marker compounds were then quantified,
analytical methods developed, and analytical fingerprint profiles generated to
standardize formulation extracts. Among the compounds isolated, a novel pair of
cyclic guanidine alkaloids is reported. To our knowledge, this is the second
reporting of 2-substituted imidazoline alkaloids isolated from a plant source.
These compounds were screened in silico for their ability to bind to the human
androgen receptor (AR), a target for anti-androgen prostate cancer therapies, and
further tested for their biological activity in AR-positive (LNCaP) and ARnegative (PC3) prostate cancer cell lines. These compounds show activity against
AR-positive LNCaP cells in the 12.5-50 µM range, while AR-negative PC3 cells
were unaffected. In addition, compounds isolated from Iresine celosia L. were
screened using drug metabolism and toxicology simulation studies in silico, to
predict the formation of reactive metabolites and their possible toxicological

endpoints using Simulation’s Plus ADMET Predictor proprietary software. The
isolation and structure elucidation of eleven compounds from the formulation, two
of which are new, the development of analytical methods to quantify their
presence within the extract, and initial in silico toxicology screening offer
information that can be used to support a level of quality production and a
reasonable expectation of safety when using this dietary supplement as directed
for the promotion of prostate health.
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1. Natural Products: History and What it Has Become
The timeless use of plants as medicine by man was formally christened a
Western science by the German C.A. Seydler in his 1815 thesis and book,
Analecta Pharmacognistica. Combining the Greek words for “drug” (φάρµακον,
pharmakon), and the verb “to know, to discover,” (γιγνώσκω, gignosko), he
coined the phrase pharmacognosy to describe the scientific field that deals with
the chemistry, biological activity, and biosynthesis of natural products, or
secondary metabolites.
The use of these specific Greek words remains to this day a fitting choice, as
pharmacognosy continues to be primarily a discipline of drug discovery [1]. The
discovery of pharmacological agents from natural sources or based on natural
pharmacophores was made possible by advancements in separation science.
Seydler’s treatise was published at a time when new methods resulting from the
rise of industrial expansion in Britain, western Europe and the United States in the
19th century allowed for the manufacture of fine chemicals, including the isolation
of medicinal substances from plants, such as quinine, camphor and ether,
ingredients employed in the pharmacy of the day [2]. This included advancements
in the large-scale extraction of drugs from plant material by means of solvents,
usually water or alcohol, which was still a function of the pharmaceutical
manufacturer at the end of the 19th century [3].
By the early years of the 20th century, researchers had indicated that the
action of “vegetable drugs” was due to the presence of definite chemical
compounds, many of which had been isolated already. Among them were certain
alkaloids, notably quinine and morphine. The isolation of these active compounds
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in a pure state had far-reaching consequences in medicine and in the industry of
fine chemicals. For one, more accurate dosing for the drugs of that time became
possible; it is important to appreciate that this had previously been impossible, as
patients were treated with crude drugs of unknown or variable composition.
Secondly, harmful effects due to the presence of impurities in the crude drugs
could be mitigated or avoided and a level of quality control of the formulated dose
could be achieved [4]. In the case of quinine, its isolation from Cinchona bark in
1820 by Pelletier and Caventou revolutionized the treatment of malaria, as it was
possible to give a measured dose of the pure alkaloid compound instead of the
nauseous bitter brews that had been the prescription since the 1630s. Thirdly,
investigation of the chemical composition of the active principles was possible.
Among other advancements, this third point led to the development of synthetic
organic chemistry, which aimed to synthesize active principles and related
substances. The advent of synthetic products, however, did not diminish the largescale extraction of drugs from plant material by means of solvents, usually water
or alcohol. At the beginning of the 20th century, preparation of plant materials
comprised about half of medicines in the United States Pharmacopeia [5].
To this day, natural products and structures derived from natural products
continue to play a vital role in the therapeutic armament [6]. Centuries of coevolution have taken place between organisms that produce these compounds
(thought by some to be produced by the organism for the purposes of protection,
to ward off predators, harmful effects of UV rays, or as a strategy to be more
widely cultivated, by pollinators or cultivators like humans, for example), and
those that use them for medicines. Therefore, it is not surprising that natural
product structures offer leads of higher quality than mass efforts to synthesize
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bioactive compounds. Natural product secondary metabolites have been honed for
biological function.
For the most part, formal research in the area of natural products chemistry
has continued to take the approach to isolate and extract single active ingredients,
to search for “silver bullet”-type molecules that may go on to be used as
pharmaceutical-like medicines. Some have made attempts to understand the
synergistic function of active ingredients [7, 8]. These “active principles” from
natural sources can be of great value in the search for bioactive molecules because
they often possess intricate architecture, with more stereogenic centers and chiral
complexity than can be synthesized in a lab. For these reasons, as well as their
coevolution among living systems, natural products have been the single most
productive source of leads for the development of drugs, and the source of most of
the active ingredients of medicines.
Emphasis on isolation of single active principles has resulted in natural
products being evaluated, both for efficacy and safety, under a pharmaceutical and
food additive-type paradigm [9]. That scientific paradigm for the evaluation of
natural products in commercial use, in the form of dietary supplements, is outlined
in the 2011 Draft New Dietary Ingredient Guidance document, which is discussed
in detail elsewhere in this work (see Chapter 4). The historical and ethnobotanical
uses of herbs have given way to evaluation and testing of dietary supplements,
mostly through the isolation of single active principles. As mentioned above, this
has allowed for desirable outcomes, like more accurate dosing, quantification, and
specifications for formulation and its testing. However, it is important to keep in
mind that the reduction of complex botanical mixtures down to single active
principles is a model in itself that simplifies at the outset. Nevertheless, the
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reduction of the action of an herbal medicine to individual active principles makes
possible their pharmacological and toxicological evaluation. Toxicology and
pharmacology, sciences that have been built on the evaluation of single active
ingredient pharmaceutical compounds and environmental toxins, is now being
applied to the evaluation of herbal medicines.
However, even when reduced to single active principles, natural products
differ structurally, in their activity, and in their modes of action from these types
of chemicals. In general, these compounds tend to differ from synthesized
pharmaceutical compounds in the structural features that they employ. Natural
products possess exceptional chemical functionality that keep them compatible
with the aqueous milieu of biological microenvironments [10]. Nature often
exploits reactive functional groups in biologically active natural products. Natural
products typically have more stereogenic centers, and are more architecturally
complex than synthetic molecules. Natural products contain relatively more
carbon, hydrogen, and oxygen, and less nitrogenated or other elements than
synthetic agents. Synthetic medicinal chemistry prefers a high proportion of
aromatic and heteroaromatic rings, fewer stereogenic centers, lower molecular
weights, lipid-soluble molecules, with a lack of chemical reactivity. Natural
products tend to be more polar, water soluble, and adaptable to fluctuations in pH.
Furthermore, single active principles isolated from botanicals that are not
necessarily developed and consumed primarily by humans as drug molecules, but
that are consumed primarily as one of many phytochemical constituents within
dietary supplement formulations in relatively minute quantity as compared with
pharmaceutical prescription dosing, present a different pharmacological profile
altogether. Standardization of extracts can reveal that what are thought to be the
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active ingredients are present in very small quantities, on the microgram,
nanogram and picogram scale – concentrations that may be well below a threshold
needed to see a toxic effect. While most of these single active principles within
the context of their use in a botanical dietary supplements can be considered safe,
there exist a few compounds that can be considered toxic.
When considered as a whole, these compounds tend to exert toxic effects
through oxidative metabolism into biologically reactive intermediates (BRIs) [1114]. When dosed properly, these compounds can also be found to exert chemopreventive effects. The overall risk/benefit of botanical dietary supplements can
be thought of as the result of BRI formation and interaction with resulting
biological targets, which likely depends on the level of reactivity and selectivity of
the BRI, as well as the dose and time of exposure.
Biotransformation of a compound into reactive metabolites is largely a
function of its chemical properties. The presence of certain chemical functional
groups has been associated with toxicity due to the formation of reactive
metabolites. Phytochemicals containing structural features like conjugated
systems, simple Michael acceptors, epoxides, carbocations, quinoids, terminal
alkenes, acetylenes, and benzodioxoles, among others, or the ability to form them,
have been commonly associated with reactive metabolite-mediated adverse effects
in botanical dietary supplements [12-15]. For decades, structural alerts have also
been used to mitigate toxic liabilities for pharmaceuticals, environmental
chemicals, and food additives, though the structural features present in these
classes of compounds tend to differ from those associated with botanical natural
products [11, 16-20]. Mitigating metabolism-related liabilities for pharmaceuticals
and environmental toxins is often accomplished through in silico screening of
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compounds for these structural alerts. This strategy has been used successfully
both by manufacturers and regulators of these products, who find these
computational SAR toxicology models to be both reasonably sensitive and
specific [17, 18, 21-25]. A similar methodology could be applied to mitigate risk
from dietary supplements, but such an approach should be specific to the risks
presented by the particular chemistry of natural products.
The benefit of this approach is a substantial reduction, replacement, and
refinement in the need for biological and particularly animal toxicological testing
required to establish the safety of chemical substances. Within the food additive
regulatory paradigm, screening for structural alerts also allows for the
development of thresholds of concern, which then trigger requirements for further
testing before the product can be introduced to the marketplace. If similar
structural alert screening could be conducted for dietary supplements, and
threshold of concern regarding a dietary supplement’s risk profile could be
determined, the extensive, resource intensive, and costly testing outlined within
the New Dietary Ingredient Draft Guidance of 2011 may not be entirely necessary
for every phytochemical ingredient present in every natural product brought to
market.
When combined with phytochemical characterization and standardization,
such an approach may help to mitigate the health risks posed by botanical dietary
supplements. The work that follows attempts to apply such an approach to the
evaluation on one of the nearly one thousand new dietary supplements brought to
market each year.
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2. Justification for and Significance of the Study
The use of natural product medicine in the form of dietary supplements in
the U.S. has increased significantly over the past two decades [26]. Since the
passage of the Dietary Supplement Health and Education Act (DSHEA) in 1994,
the botanical dietary supplement market in the US has grown from $2.9 billion in
1995 to $4.8 billion in 2008 [27, 28]. It is estimated that over one thousand new
dietary supplement products entering the market each year [29]. For the natural
products chemist, this trend translates into new challenges to evaluate the quality
of botanical ingredients, which is linked directly to the safety and efficacy of the
final dietary supplement product.
For all their popularity, however, many commercial botanical products are
poorly defined scientifically. In the United States, consumers take it on faith that
the supplement they are ingesting is the same as is listed on the label, and that it
contains the reportedly “active” constituents they seek [30]. While a number of
commonly used herbs are generally regarded as safe (GRAS), many herbs that
have been in use for centuries as traditional medicines are not necessarily
guaranteed to be either safe for consumption or efficacious, in part due to a lack of
scientific investigation. In the words of the Institute of Medicine, “the same
principles and standards of evidence of treatment effectiveness apply to all
treatments, whether currently labeled as conventional medicine or [as]
complementary and alternative medicine (CAM)” [31, 32]. Whether botanical or
synthetically derived, medicines should be made in a safe and reproducible
manner, with an understanding of the degree of efficacy related to the medicine’s
intended use. The study goes on to explain that in the case of CAM, “safety
trumps efficacy”, and “the absence of evidence of effectiveness does not imply
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absence of effectiveness” [29]. Whether or not clear evidence of effectiveness for
a given condition is found, these therapies can and should be scientifically
investigated, for their safety as well as for the presence of known and/or novel
phytochemicals present that may possess biological activity.
Odyliresin™ is a botanical supplement formulation currently marketed to
humans for the promotion of prostate health [33]. The tincture is comprised of a
30% ethanol extract of the botanical Iresine celosia. The plant is a member of the
Amaranthaceae family and goes by several botanical synonyms and common
names, as listed in Table 1 [34-38].

8

Table 1: Botanical Synonyms and Common Names for Iresine
celosia[34-38]
Taxonomical synonym for Iresine celosia L.

Common names

Iresine diffusa
Humb. & Bonpl. ex Willd.

Juba bush
Bloodleaf, Camarón, shrimp
plant, hierba de la plata (silver
herb, Central America),
plumaria (little feather,
Columbia), velo de princessa
(princess’s veil, Guatemala),
nerve wist

Iresine canescens
Humb. & Bonpl. ex Willd
Iresine celosioides (L.)

tlatlancuaya

Iresine chalk

tlatlancuaya

Iresine elongata
Humb. & Bonpl. ex Willd
Iresine paniculata (L.)
Kuntze, non Poir
Iresine flavescens
Humb. & Bonpl. ex Willd
Iresine gracilis
Humb. & Bonpl. ex Willd
Alternanthera flavescens
Humb. & Bonpl. ex Willd
Iresine calea (Ibftenz)
Iresine latifolia
Gomphrena latifolia
Iresine laxa

Amargosilio, tepozan, erba del
tabardluo herba de la calenture;
mosqultero; clacancauayo
(derived from the Nahuatl
tlatiancua-ye “which has knees,”
referring to jointed stems)

Alternanthera paniculata
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The plant is native to the Southeastern United States, Mexico, Central and
South America, and the West Indies. It has a history of use by indigenous peoples,
including the Highland Mayans of Chiapas, Mexico, who referred to the plant as
tlatlancuaya [39]. A variety of anecdotal indications accompany the plant,
including its ancient use for the treatment of skin conditions such as dropsy,
reproductive health, gonorrhea and malaria [40]. The plant is also one of several
ingredients included in Jamaican root tonics for male virility and overall health,
among other varied indications [35, 36, 41-43]. The Odyliresin™ formulation of
Iresine celosia has been marketed as a treatment of tumorigenic conditions at
large and for epilepsy as far back as 1965, and more recently as an antioxidant
[44].
Previous phytochemical analysis may have been conducted on the plant
under one of the plant’s many botanical synonyms. Using classic techniques for
the isolation and elucidation of phytochemicals, Djerassi and his colleague Pierre
Crabbé reported two main chemical constituents of the plant. The first was the
then unknown drimane iresin, reported in 1953, which took six years to elucidate
its structure [39, 45-49]. Its spectral assignment was not reported until 2005 in a
paper that also identified the presence of the previously reported compounds
triacontanol, beta-sitosterol, stigmasterol, alpha-amyrin-3-O-beta-Dglucopyranoside, beta-amyrin-3-O-beta-D-glucopyranoside, beta-sitosteryl-betaO-D-glucopyranoside and iresin [50]. The 2005 paper by Rios and colleagues also
identified three new drimanes from the plant: 3,14-dihydroxy-17,8-drimen-11,12acetonide; 3,7,14-trihidroxy-18,9-drimen-11,12-olide; and 3,7,14-trihydroxy-18,9drimen-11,12-olide. The 2005 Rios paper did not report a second compound
isolated by Djerassi and Crabbé, tlatlancuayin, or 2',5-dimethoxy-6,7-
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[methylenebis(oxy)]isoflavone;2',5-Dimethoxy-6,7 methylenedioxyisoflavone
[48]. The drimane structures, along with iresin and isoflavone tlatlancuayin, are
listed in Table 2 and Figure 1. However, it is not clear that these plants were
definitively identified as Iresine celosia.
This work represents the first phytochemical evaluation of the Iresine
celosia herbal supplement formulation.
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Table 2: Compounds Isolated from Iresine diffusa
Compounds Isolated From Iresine diffusa
iresin
tlatancuayin
3-beta,7-alpha,14-trihydroxy-delta-8,9-drimen-11,12-olide
3-beta,7-beta,14-trihidroxy-delta-8,9-drimen-11,12-olide
3-beta,14-dihydroxy-delta-7,8-drimen-11,12-acetonide
dimethoxy-6,7-[methylenebis(oxy)]isoflavone;2',5-Dimethoxy6,7 methylenedioxyisoflavone
triacontanol
beta-sitosterol
stigmasterol
alpha-amyrin-3-O-beta-D-glucopyranoside
beta-amyrin-3-O-beta-D-glucopyranoside
beta-sitosteryl-beta-O-D-glucopyranoside

12

Figure 1: Structures of Chemical Constituents Identified in Iresine
diffusa
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3. Aims of This Work
The work set out to evaluate the quality, safety and efficacy of the dietary
supplement Odyliresin™ formulation of the botanical Iresine celosia through the
following aims:
•

Aim 1: Ensure quality through biological classification of plant
starting material, the isolation and characterization of known and/or
novel chemical constituents of the Iresine celosia extract, and the
development of methodologies for preparation where needed.

•

Aim 2: Evaluate the safety of isolated phytochemicals using in silico
drug metabolism and toxicology simulation studies, to predict possible
metabolites generated in vivo and their possible toxicological
endpoints using ADMET predictor proprietary software.

•

Aim 3: Biological investigation using in-house bioassays and in silico
molecular docking experiments with targets involved in prostate
cancer, with a focus on the human androgen receptor.

4. Outline of Chapters
Chapter 1 set a backdrop for the history and current conditions under which
the present study is being conducted. We set out our aim of investigating
phytochemically a traditional herbal medicine made dietary supplement, currently
used in humans to promote prostate health.
Chapter 2 goes into detail describing the isolation and structural elucidation
of 11 compounds from the Iresine celosia Odyliresin™ formulation extract, with
the reporting of two new and structurally rare (see Table 3) guanidine alkaloids
that show activity as possible androgen receptor (AR)-binders in silico, and inhibit
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growth of AR-dependent prostate cancer cells. Until now, guanidine alkaloids
have not been found in Iresine celosia.

Table 3: Plant Species Known to Contain Guanidine
Alkaloids
Order
Asterales
Caryophyllales
Fabales
Fabales
Fabales
Malpighiales
Ranunculales
Solanales

Family
Asteraceae
Plumbaginaceae
Fabaceae
Fabaceae
Fabaceae
Eupgorbiaceae
Ranunculaceae
Solanaceae

Genus, species
Verbesina peraffinis
Plumbago zeylania
Canavalia rosea
Milletia laurentii
Psterogyne nitens
Alchornea cordifolia
Cimicifuga racemosa
Solanum cernuum

Chapter 3 outlines a method for the HPLC-analysis and the calibration of
these two new, species-specific compounds as analytical standards to identify the
extract chemically, as well as an analytical fingerprint profile to which a crude
chromatogram can be compared. Chapter 3 also allows for understanding of
concentrations of these compounds in dosing of the supplement in its current
formulation.
Chapter 4 discusses current regulatory environment calling for more
stringent testing of botanicals for the evaluation of their safety and risk, a
perspective on the proper evaluation of risks presented by phytochemicals used as
medicine, and how in silico ADME/Tox screening can be applied to the safety
evaluation by regulators and manufacturers of botanical dietary supplements, as it
has been for food additives, environmental toxins, and pharmaceuticals. This
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strategy offers an opportunity for cost-savings, and reduced and conscientious use
of animal testing,
Chapter 5 evaluates the ability of these compounds to form reactive
metabolites, the ability of parent compounds and metabolites to cause CYP
enzyme inhibition, and for other structural features that may be related to toxic
liabilities. This is accomplished through the use of Simulation’s Plus ADMET
Predictor software designed for ADME/TOX (PK) screening.
At the end of this work, it is hoped that perspective on the chemistry,
biological activity, and potential risk profile of this particular botanical
formulation is gained, through the understanding of pharmacognosy.

16

References
1.
2.
3.
4.
5.

6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.

18.

Dias, D.A. et al., A Historical Overview of Natural Products in Drug
Discovery. Metabolites, 2012. 2: p. 303-336.
Taylor, N., Plant Drugs that Changed the World. 1965, Cornwall, NY:
The Cornwalll Press.
Singer, C., Holmyard, E.J., Hall, A.R., Willians, T.I. A History of
Technology: 1850 to 1900, ed. Vol. 5. 1958, New York: Oxford University
Press.
Foster, S., A Brief History of Adulteration of Herbs, Spices, and Botanical
Drugs. HerbalGram, 2011(92): p. 42-57.
Craker, L.E., Gardner Z.E., Medicinal plants and tomorrow's pharmacy:
an American perspective. Medicinal and Aromatic Plants: Agricultural,
Commercial, Ecological, Legal, Pharmacological and Social Aspects, ed.
R.J. Bogers, Craker, L.E., Lange, D. Vol. 17. 2006.
Newman, D.J., Cragg, G.M., Natural Products as Sources of New Drugs
over the Last 30 Years from 1981 to 2010. J. Nat. Prod., 2012. 75(3): p.
311-35.
Adams, L.S., et al., Analysis of the interactions of botanical extract
combinations against the viability of prostate cancer cell lines. Evid Based
Complement Alternat Med, 2006. 3(1): p. 117-24.
Junio, H.A., et al., Synergy-directed fractionation of botanical medicines:
a case study with goldenseal (Hydrastis canadensis). J Nat Prod, 2011.
74(7): p. 1621-9.
Spelman, K., “Silver Bullet” Drugs Vs. Traditional Herbal Remedies:
Perspectives on Malaria. HG J Am Bot Counc., 2009. 84: p. 44-55.
Clardy, J., Walsh, C. Lessons from natural molecules. Nature, 2004.
432(7019): p. 829-37.
Dietz, B.M., Bolton, J.L., Biological reactive intermediates (BRIs) formed
from botanical dietary supplements. Chemico-Biological Interactions,
2011. 192: p. 72–80.
Chen, X.W., Zhou, S.F. et al. Herbal bioactivation, molecular targets and
the toxicity relevance. Chemico-Biological Interactions, 2011. 192: p.
161–176.
Zhoua, S.F., et al. Herbal bioactivation: The good, the bad and the ugly.
Life Sciences, 2004: p. 935-968.
Zhou SF, et al., Metabolic activation of herbal and dietary constituents
and its clinical and toxicological implications: an update. Curr Drug
Metab, 2007. 8(6): p. 526-53.
Njuguna, N.M. et al., Identification and Characterization of Reactive
Metabolites in Natural Products-Driven Drug Discovery. J. Nat. Prod.,
2012. 75: p. 507−513.
Bailey, A.B., Chanderbhan, N., et al., Regulatory Toxicology and
Pharmacology, 2005. 42: p. 225.
Matthews, E.J. et al., An analysis of genetic toxicity, reproductive and
developmental toxicity, and carcinogenicity data: I. Identification of
carcinogens using surrogate endpoints. Regulatory Toxicology and
Pharmacology, 2006. 44: p. 83–96.
Matthews, E.J. et al., An analysis of genetic toxicity, reproductive and
developmental toxicity, and carcinogenicity data: II. Identification of
17

19.
20.

21.

22.
23.
24.

25.

26.
27.
28.
29.
30.
31.
32.
33.
34.

genotoxicants, reprotoxicants, and carcinogens using in silico methods.
Regulatory Toxicology and Pharmacology, 2006. 44: p. 97–110.
Keshava, C. et al., CYP3A4 Polymorphisms—Potential Risk Factors for
Breast and Prostate Cancer: A HuGE Review. American Journal of
Epidemiology, 2004. 160(9): p. 17.
Kalgutkar, S.A. et al. Mechanism-Based Inactivation (MBI) of Cytochrome
P450 Enzymes: Structure−Activity Relationships and Discovery Strategies
To Mitigate Drug−Drug Interaction Risks. J. Med. Chem., 2012. 55: p.
4896−4933.
Frid, A.A., et al., Prediction of drug-related cardiac adverse effects in
humans-B: Use of QSAR programs for early detection of drug-induced
cardiac toxicities. Regulatory Toxicology and Pharmacology, 2010. 56: p.
276–289.
Walker, J.D., Applications of QSARs in toxicology: a US Government
perspective. Journal of Molecular Structure (Theochem), 2003. 622: p.
167–184.
Cronin, T.D. et al., Use of QSARs in International Decision-Making
Frameworks to Predict Health Effects of Chemical Substances.
Environmental Health Perspectives, 2003. 111(10).
Matthews, E.J. et al., A comprehensive model for reproductive and
developmental toxicity hazard identification: II. Construction of QSAR
models to predict activities of untested chemicals. Regulatory Toxicology
and Pharmacology, 2007. 47: p. 136–155.
Matthews, E.J. et al., Identification of structure-activity relationships for
adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR
systems for early detection of drug-induced hepatobiliary and urinary
tract toxicities. Regulatory Toxicology and Pharmacology, 2009. 54: p.
23-42.
Barnes, P., Powell-Griner, E., McFann, K, Nahin, RL, Complementary and
Alternative Medicine Use Among Adults: United States, 2002. Adv. Data,
2004. 343: p. 1-19.
Nutrition Business Journal. 1998, June, Boulder, CO: New Hope Natural
Media, Penton Media Inc.
Nutrition Business Journal. 2009, September, Boulder, CO: New Hope
Natural Media, Penton Media Inc.
Dietary Supplements: A Framework for Evaluating Safety. 2004, Institute
of Medicine: Washington, DC.
Khan, I., Smillie, T., Implementing a “Quality by Design” Approach to
Assure the Safety and Integrity of Botanical Dietary Supplements. J. Nat.
Prod., 2012. 75: p. 1665-1673.
National Nutritional Foods Association, NNFA List of Dietary
Suppplement Ingredients in Use Before October 15, 1994. 1996, April 26.
Bondurant, S.C., Complementary and Alternative Medicine in the United
States, T.N. Academies, Editor. 2005, Institute of Medicine of the National
Academies: Washington, DC. p. 337.
http://iresine.com/formula/
http://iresine.com/formula/Odyliresin™/history
http://iresine.com/formula/Odyliresin™/physicians. [Accessed 10/09/12]
H. Ayuntamiento de Villa de Allende, Anexos - Programa de
Ordanameinto Ecologico del Municipio de Villa de Allende - Listados de

18

35.
36.
37.
38.
39.
40.
41.

42.
43.
44.
45.
46.
47.
48.
49.
50.

especies de flora y fauna reportadas para el municipio de Villa de Allende,
Listados de especies de flora y fauna reportadas para el municipio de Villa
de Allende. Allende, Editor. 2003-2006: Allende, Mexico.
Davy, H., Sir, 1778-1829, Collected works of Sir Humphry Davy. Edited
by his brother John Davy. With a new introd. by Robert Siegfried. 1972,
New York: Johnson Reprint Corp.
Austin, D.F., Honychurch, P.N., Florida Ethnobotany. 2004: CRC Press.
United States Department of Agriculture and Natural Resources
Conservation Service. Plants Database. Accessed 2013 February 1.
Available from: http://plants.usda.gov/java/nameSearch.
Standley, P.C., Trees and Shrubs of Mexico, Part 2. 1922, Government
Printing Office: Washington, DC.
Djerassi, C., Sengupta, P., Herran, J., Walls, F., The Isolation of Iresin, a
New Sesquiterpene Lactone. J. Am. Chem. Soc., 1953. 76: p. 2966-2968.
Bussmann, R.W., Glenn, A., Medicinal plants used in Northern Peru for
reproductive problems and female health. Journal of Ethnobiology and
Ethnomedicine, 2010. 6(30).
Luziatelli, G., Sorensen, M, Theilade, Ida, Molgaard P., Asháninka
medicinal plants: a case study from the native community of Bajo
Quimiriki, Junín, Peru. Journal of Ethnobiology and Ethnomedicine, 2010.
6(21): p. 1-23.
Schmidt, C., et al., Biological studies on Brazilian plants used in wound
healing. Journal of ethnopharmacology, 2009. 122(3): p. 523-32.
Mitchell, S., The Jamaican root tonics: a botanical reference. Focus on
Alternative and Complementary Therapies, 2011. 164(4): p. 271-280.
Cantero, A., Osler LIbrary Antonio Cantero Fonds Collection. 1920-1976,
McGill University: Montreal, Candada.
Djerassi, C., Rittel, W., Iresin (Part 2): A New Fundamental Sesquiterpene
Skeleton. 79: p. 3528-3534.
Djerassi, C., Donovan, F.W., Burstein, S., Mauli, R., Iresin (Part 3):
Reactions of the Glycol Stem. J. Am. Chem. Soc., 1958. 80: p. 1972-1978.
Djerassi, C., Burstein, S., Iresin Part 5 - Complete Structure and Absolute
Configuration. Tetrahedron, 1959. 7: p. 37-46.
Crabbe, P., Leeming, P.R., Djerassi, C., Naturally occurring oxygen
heterocyclics. III. The structure of the isoflavone tlatlancuayin. Journal of
the American Chemical Society, 1958. 80: p. 5258-63.
Djerassi, C., Burstein, S., The Structure and Absolute Configuration of
Iresin. J. Nat. Prod., 1958. 80: p. 2593.
Rios, M.Y. and L.A. Berber, 1H and 13C assignments of three new
drimenes from Iresine diffusa Humb. & Bonpl. ex Willd. Magnetic
resonance in chemistry : MRC, 2005. 43(4): p. 339-42.

19

Rare Cyclic Guanidine Alkaloids from Iresine celosia
Caroline Killian †, Tao Yuan †, Liya Li †, Alvin C. Bach II †, Brendan
McKeown‡, Luke McDougall‡, Robert A. Hurta ‡, and Navindra P. Seeram †*

† Bioactive Botanical Research Laboratory, Department of Biomedical and
Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island,
Kingston, Rhode Island 02881, United States
‡ Department of Biology, University of Prince Edward Island, 550 University
Avenue, Charlottetown, PE, C1A 4P3, Canada. E-mail: rhurta@upei.ca; Fax:
+902-566-0740; Tel: +902-566-0476
*Corresponding author. Tel.: 401-874-9367, Fax: 401-874-5787, E-mail:
nseeram@uri.edu

This manuscript is written and formatted for the Journal of Natural Products.

20

Abstract: Among eleven compounds isolated from the plant, two new,
structurally rare cyclic guanidine alkaloids have been isolated and characterized
from the aerial portion of Iresine celosia. The structures of 1 and 2, celosiadine A
and B, were confirmed by 1D and 2D NMR spectroscopy as well as HRESIMS.
Since a commercial formulation of the botanical is currently consumed by humans
for the purpose of promoting prostate health, compounds isolated from the plant
were screened in silico for their ability to bind to the human androgen receptor
(AR). Compounds 1 and 2 showed favorable binding affinity (-6.6 and -6.8
kcal/mol respectively) in wild type AR and mutant AR T877A and H874Y crystal
structures that were then evaluated for their activity in vitro against androgenindependent prostate cancer cell line PC3, and the androgen-sensitive prostate
adenocarcinoma cell line LNCaP. Preliminary in vitro work confirmed findings
from the in silico docking experiments. Statistically significant changes were
observed in LNCaP cells following 24 hour exposure at concentrations ranging
from 12.5 - 50 µM were observed, while PC3 cells remained almost entirely
unaffected by the compounds, suggesting that the compounds isolated from this
formulation could have therapeutic implications in androgen-dependent prostate
cancers.
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Introduction:
For centuries in Asia, Africa and India, phytotherapy has been considered
a first line treatment for conditions of the prostate, and in the United States and
Europe, the number of people using medicinal plants for prostate related
conditions, including prostate cancer, has been on the rise [1]. Iresine celosia, a
member of the family Amaranthaceae, is native to the Southeastern United States,
Mexico, Central and South America, and the West Indies. The plant has 14 or
more botanical synonyms [2-5], and has been previously investigated for its
phytochemistry under the name Iresine celosiodies [6-11], and more recently
under the name Iresine diffusa [12]. It has a history of use as a remedy by
indigenous peoples, including the Highland Mayans of Chiapas Mexico, who
referred to the plant as tlatlancuaya [9]. A variety of anecdotal indications
accompany the traditional use of the plant, including those for skin conditions like
dropsy, gonorrhea and malaria. A formulation of the aerial portions of the plant
was developed in the 1960s and has since been promoted for a variety of
applications, including epilepsy, as an antioxidant, and for promoting health in
tumorigenic conditions at large, especially of the prostate [33]. This formulation,
comprised of a 30% ethanol extract of the aerial portions of the plant, is currently
consumed by humans. However, the chemical constituents of this formulation are
not known. Herein, the isolation and structure elucidation of two new guanidine
alkaloids, celosiadine A and B (1, 2), along with the purification of
hydroxygalegine (3), and eight other compounds from the formulation and aerial
portions of the plant are reported (Fig. 2).
As a class, guanidine compounds are relatively rare as secondary
metabolites, and are found more commonly in marine sponges than in higher
22

plants. They posses a wide range of biological activity and impressive chemical
structures [13, 14]. To our knowledge, this is the first reporting of guanidine
alkaloids in the Amaranthaceae family, the second reporting within the
Caryophyllales order, and the second ever reporting of cyclic guanidine alkaloids
isolated from a plant source [15]. Cyclic guanidine alkaloids have been found as
the products of secondary metabolism in sponges. Sponge-derived guanidine
alkaloids, and imidazoles in particular, are well known for their anti-cancer
properties [16]. Thus, as the formulation is used for promoting health in
tumorigenic conditions, especially that of the prostate, further biological
experiments were conducted to evaluate the therapeutic potential of the
compounds.
In silico docking experiments have previously helped to elucidate the anticancer activity of plant natural product compounds against prostate cancer cell
lines expressing the T877A mutation [17, 18]. Small molecule plant natural
products like epigallocatechin gallate from green tea (Camellia sinensis) and
atraric acid from Pygeum africanum have been found to act as anti-androgens,
both active at an in vitro concentration of 10 µM. In particular, atraric acid has
demonstrated the ability to inhibit transport of the AR to the nucleus, and has been
shown to efficiently repress the growth of androgen-dependent LNCaP prostate
cancer cells, but not androgen-independent cell lines, like PC3 [19]. Therefore, to
test whether compounds isolated from Iresine celosia could act in a similar
fashion, Compounds 1 and 2 were screened in silico for their ability to bind the
androgen receptor crystal structures for both wild type and prostate cancer-related
mutants.
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Compounds 1 and 2 were screened in silico for their ability to bind to the
crystal structures of AR wild type (PDB ID: 2YHD), and two mutant varieties
relevant to the progression of prostate cancer with crystal structures available in
the Protein Databank, T887A (PDB ID: 1I37) and H874Y (PDB ID: 2Q7K) [20,
21]. Binding affinities resulting from docking experiments were compared with
the AR's natural ligands, testosterone and dihydrotestosterone (DHT), known nonAR binders beta-sitosterol and stigmaterol, known AR-binding small molecule
natural products EGCG and atraric acid, and compounds implicated in BPHrelated prostate health: apigenin, emodin, baicalein, genistein, icaritin,
xanthohumol (see Tables 7-9) [22]. The lab constituted Iresine celosia
formulation extract, and pure Compounds 1 and 2, were then evaluated for their
ability to inhibit prostate cancer cell growth as compared to control, using LNCaP
prostate cancer cells, that express the AR mutant T877A, and PC3 ARindependent cell lines.
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Results and Discussion:
In total, eleven compounds were isolated from Iresine celosia (Fig. 2).
Alongside two novel cyclic guanidine alkaloids, celosiadine A and B, compounds
(1) (25 mg) and (2) (5.7 mg) respectively, a third known guanidine containing
alkaloid, hydroxygalegine, was isolated, compound (3) (2.3 mg). The 30% ethanol
extract of the plant also posses a number of nucleosides, among them, 2’deoxyuridine (7) (3.5 mg), 2’deoxy-thymidine (8) (13 mg), uracil (4) (0.7 mg) and
adenine (5) (2.8 mg), along with some additional small molecule structures, 3indole-carboxyllic acid (6) (2.8 mg), anisic acid (10) (1.8 mg), and
phenylacetamide (11) (3 mg). The identity of these structures was assigned based
on analysis of the 1H spectra and the 13C NMR spectra and in accord with
assigned values from the literature.

Biosynthesis
The biosynthesis of the two new compounds, celosiadine A and B, could
be explained by the isolation of a third, known compound whose biosynthesis has
been investigated through the use of radiolabeled feeding experiments. Alongside
celosiadine A and B, or compounds (1) and (2) respectively, 4-hydroxygalegine
(3) was also isolated. Its parent compound galegine (1-guanidino-3-methyl-2butene) is a guanidine derivative found together with hydroxygalegine in the seeds
of Goat’s Rue, Galega officinalis. Galegine is synthesized in the shoot of the plant
and is found to accumulate in the seeds. Surprisingly, its isoprenoid hydrocarbon
chain does not arise from the mevalonic acid-isopentenyl pyrophosphate sequence
of terpenoid biosynthesis. Rather, a series of radiolabeling experiments conducted
between 1965-1968 by Reuter et al. showed that the guanidino group is added by
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a transamidation of an amidino group of arginine [23-26]. More specifically, 14Cradiolabeled arginine and its biosynthetic precursor, ornithine, were both applied
to young seedlings of Galega officinalis. Pyruvate was found to be a precursor of
the galegine compound, but mevalonic acid was poorly incorporated. Later, when
14

C-amidino labeled guanidino-acetic acid hydrochloride was added to seedlings

of Galega officinalis, 90% of radioactivity was found in the amidino group of
galegine, suggesting that guanidine-acetic acid is the biosynthetic precursor of
galegine. Thus, it is likely that related compounds 1 and 2 are biosynthesized in a
similar manner (see Figure 4).
A simple rearrangement of the hydroxygalegine molecule could allow for
a cyclization of the compound between the double bond and the free amine.
Double bond isomerization could account for the imidazoline ring. The primary
alcohol at the end of the alkyl chain off of the now cyclized imidazoline ring
could be oxidized to form a carboxylic acid. Condensation of the cyclized
compound with the alkyl moiety of an additional guanidinoacetic acid molecule
could be responsible for the additional side chain seen in Celosiadine B.
Nucleophilic attack of an alcohol group from water results in the alkene
isomerization of the double bond into the terminal alkene seen in Celosiadine A.
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Spectral Analysis
Compound (1), 2-[2-Amino-1-(2-hydroxy-3-methyl-3-butenyl)-4imidazolinyl]propionic acid, a light yellow amorphous solid, was assigned the
name Celosiadine A, and assigned the formula C11H19N3O3 based on HRESIMS
data at m/z 242.1500 [M+H]+ (calcd C11H19N3O3, for 242.1499). The IR
absorptions revealed the presence of peaks at 3380 cm-1 and 1700 cm-1, indicating
the carboxylic acid functionality; a broad band (3400-2000 cm-1) indicated N-H,
and an additional band at 1600 cm-1 supported the presence of the guanido group.
Detailed analysis of the 1D and 2D NMR (1H-1H COSY, HSQC, HMBC)
data allowed for the construction of the structure of Compound (1). The 1H and
the 13C NMR spectra (Table 4) characteristic of a guanidine moiety (δC 158.75), a
carboxylic acid group (δC 175.60), a quaternary carbon (δC 145.93) of a terminal
vinyl group (δC 112.16), also indicated by the presence of two singlets at 5.07 and
4.93 (H-1) that integrated for one proton each. In addition, two methyls, two other
methylenes, and three methines were detected.
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Table 4. Spectral Assignments for Compound (1)
Position

δ C (mult.) δ H (mult., J in
Hz)

COSY

1
2
3
4

112.16, 2H 5.07, 4.93, s
H-3, H-5
145.93
71.29, 1H 4.22, dd (7.8, 3.9) H-1, H-4
48.70, 2H 3.42, dd (15.1, 3.9) H-3
3.38, dd (15.1, 7.8) H-3
H-1, H-3

HMBC
C-5, C-3
H-5, H-4, H3, H1
C-5, C-4, C-2, C-1
C-3, C-2, C-4’, C-3”, C2”
C-3, C-2, C-4’, C-3”, C2”
C-3, C-1

5
6
3'
4'
1"
2"
3"
4"

18.67, 3H

1.77, s
8.42, s
7.87, s

158.75
12.92, 3H
43.79, 1H
54.54, 1H
52.60, 2H

H-4, H-4”, H-3”
1.18, d (7.8)
H-2”
C-5”, C-3”, C-2”
2.59, m
H-3”, H-1” C-5”. C-3”, C-1”
4.11, m (10.1, 6.6) H-4”, H-2” C-5”, C-4”, C-2”, C-1”
3.92, dd (10.1)
H-3”
C-4’, C-3”, C-2”
3.55, dd (10.1, 6.6) H-3”
C-4’, C-3”, C-2”

5”
6"

175.60
12.51, s
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There were 1H−1H COSY correlations between H-5/H-1/H-3/H-4, and
between H-4"/H-3"/H-2"/H-1". In the HMBC spectrum, the guanidine carbon
signal at δC 158.75 showed correlations with protons δH 3.92 and 3.55 (H-4), and
δH 3.42 and 3.38 (H-4"), and δH 4.11(H-3"). The carboxylic acid group at δC
175.60 had correlations with protons δH 4.11(H-3") 2.59 (H-2") and 1.18 (H-1").
The quaternary carbon at δC 145.93 correlated with protons δH 5.07 and 4.93 (H1), δH 4.22 (H-3), 3.42 and 3.38 (H-4), and δH 1.77 (H-5). The terminal alkene at
δC 112.16 was shown to correlate with protons δH 4.22 (H-3) and 1.77 (H-5). Also,
the carbon at the secondary alcohol, δC 71.29, revealed correlations with protons
δH 5.07 and 4.93 (H1), and 3.42 and 3.38 (H-4). For key HMBC (H→C) and
1

H−1H COSY correlations, see Figure 3.
The relative configuration of stereocenters at C-3" and C-2" was

determined by 1D and 2D NOESY experiments, with emphasis on couplings at
protons C-4" to protons at these stereocenters (see Figure 14-15). The proton H-4"
at δH 3.92 showed the effect of being coupled to H-3" at δH 4.11, while proton H4" at δH 3.57 showed the effect of being coupled to the H-2" at δH 1.18. This
information provided information about the relative configuration of these protons
with respect to each other, but could not be extrapolated to provide information on
the absolute stereochemistry of these stereocenters. In addition, the proton H-1 at
δH 4.93 was found to be coupled to H-5 at δH 1.77, while H-1 at δH 4.93 was
coupled to H-3 at δH 4.22, providing further confirmation of the assignment of the
terminal alkene to its position on the alkyl chain substituent branching off from
the imidazoline ring.
Chiral derivatization of the stereocenter at the secondary alcohol present
at C-3 using Mosher’s esterification failed, perhaps due to the conformational
flexibility and rotatability of both the imidazoline ring’s side chains. With three
stereocenters, eight stereoisomers are possible, and it is possible that all eight may

31

be present when isolated from the crude botanical mixture. Attempts to crystalize
the compound were also unsuccessful. To resolve the absolute configuration of
stereocenters present within Compound (1), theoretical calculation of electronic
circular dichroism (ECD) by time-dependent density functional theory (TDDFT)
will be used. This method has previously been used to determine the absolute
configuration of highly flexible compounds, including alkaloids, as well as other
conformationally rigid natural product molecules [51].
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Figure 3. Key 1H -> 1H COSY (bold lines) and HMBC (H->C)
(arrows) Correlations for Compound (1)
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Table 5. Spectral Assignments for Compound (2)
Position

δ C (mult.)

δ H (mult., J in
Hz)

COSY

HMBC

1
2
3
4
5
6
3'
4'
1"
2"
3"
4"

18.17, 3H
138.45
117.42
41.87, 2H
25.86, 3H

1.73, s

H-4

3.95, dd (7.1)
1.79, s
5.18, t (7.1)
8.05, s

H-6, H-1
H-4
H-4

C-5, C-3, C-2
H-5, H-4, H-1
H-5, H-4, H-1
C-3, C-2, C-4’, C-4”
C-3, C-2, C-1
C-5, C-1

5”
6"

175.59

159.14
12.87, 3H
43.73, 1H
54.53, 1H
50.88, 2H

1.14, d (7.1)
2.56, m
4.11, m (10.1, 6.3)
3.72, dd (10.1)
3.36, dd (10.1, 6.3)
12.69, s
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H-2”
H-3”, H-1”
H-4”, H-2”
H-4”, H-3”
H-4”, H-3”

H-4, H-4”
C-5”, C-3”, C-2”
C-5”. C-3”, C-1”
C-5”, C-4”, C-1”
C-3”, C-2”
C-3”, C-2”
H-2”, H-1”

Compound (2), 2-[2-Amino-1-(3-methyl-2-butenyl)-4imidazolinyl]propionic acid, a light yellow powder, is chemically related to
compound 1, with a molecular formula of C11H19N3O2 as determined by
HRESIMS at m/z 226.1547, [M+H]+ (calcd for C11H19N3O2, 226.155). The
NMR chemical shifts of compound (2), presented in Table 5, were similar to that
of Compound (1), except for differences in the carbon chemical shifts of C-1 (δC
18.17) and C-3 (δC 117.42), reflecting a change in the placement of the double
bond between the two compounds. The IR spectrum of Compound (2) was similar
to Compound (1), in that it revealed the presence of peaks at (3500-3350) and
1700, indicating the carboxylic acid functionality; 3400-2000 broad indicated NH, and an additional band at 1600 supported the presence of the guanido group,
with slight variation with the peak at 1000 cm-1 more pronounced in compound
(2) than in the fingerprint region from its related compound (1).
The structure of compound (3), hydroxygalegine, was determined through
analysis of the 1D and 2D NMR experiments (see Table 6) and comparison with
the literature [27]. The isolation of this compound helped to support rationale for
the proposed biosynthesis of compounds (1) and (2) as deriving from arginine.
In addition, eight other compounds were isolated from the butanol fraction of
the 30% ethanol extract of the plant. Among them were nucleosides 2’deoxyuridine (7), 2’deoxy-thymidine (8), uracil (4), and adenine (5) [52]. Three other
small molecule structures, 3-indole-carboxyllic acid (6), anisic acid (10), and
phenylacetamide (11) were also isolated and confirmed by comparison with NMR
spectra from the literature [53-55].
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Table 6. Spectral Assignments for Compound (3),
Hydroxygalegine
Position

δ C (mult.)

2
5
6
7
8
10

156.34
45.5, 2H
119.52, 1H
140.28
60.53, 2H
20.97, 3H

δ H (mult., J in Hz) COSY

HMBC
H-5

4.09, d (7.1)
5.31, t (7.1)

H-10, H-6
H-10, H-5

4.12, s
1.81, s

H-6, H-5
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H-8, H-5. H-10
H-8, H-5. H-10
H-6, H-10
H-6, H-8

Compounds (1) and (2) were screened in silico for their ability to bind to
the crystal structures of AR wild type (PDB ID: 2YHD), and two mutant varieties
relevant to the progression of prostate cancer with crystal structures available in
the Protein Databank, T887A (PDB ID: 1I37) and H874Y (PDB ID: 2Q7K) [20,
21]. Binding affinities resulting from docking experiments were compared with
the AR's natural ligands, testosterone and dihydrotestosterone (DHT), known nonAR binders beta-sitosterol and stigmaterol, known AR-binding small molecule
natural products EGCG and atraric acid, and compounds implicated in BPHrelated prostate health: apigenin, emodin, baicalein, genistein, icaritin,
xanthohumol (see Tables 7-9) [22]. Compound (1) and (2) were found to have
binding affinities comparable to atraric acid (-6.1, -6.3, -6.8 kcal/mol in 2YHD,
1I37 and 2Q7K respectively), and EGCG (-6.8, -4.2, -6.0 kcal/mol in 2YHD, 1I37
and 2Q7K respectively) but did not bind as well as natural ligand testosterone (11.2, -11.2, -11.8 kcal/mol in 2YHD, 1I37 and 2Q7K respectively) or DHT (-10.9,
-10.2, -11.3 8 kcal/mol in 2YHD, 1I37 and 2Q7K respectively). The top three
modes of each compound docked are listed in Tables 7-9.
Because of promising in silico results, we sought to evaluate the ability of
celosiadine A and B to inhibit the growth of prostate cancer cell lines in vitro.
Testing of compounds (1) and (2) in in vitro prostate cancer cell assays supported
in silico screening results by inhibiting the growth of AR-sensitive prostate cancer
cells. Compound (1) and (2) were tested at 12.5, 25, and 50 µM concentrations.
The butanol extract was tested at the 50 and 250 ppm concentration. Exposure
time was for 6 hours and 24 hours. Statistically significant changes in the LNCaP,
AR-sensitive cell line, were observed following 24 hours of exposure from the
compounds as well as the crude extract from which they were derived. This effect
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was not observed in the PC3, androgen-independent prostate cancer cell lines
(Fig. 34, 35, 36).
These results suggests that celosiadine A and B may be the health relevant
principles responsible for the use of Iresine celosia in promoting prostate health,
and that their mechanism of action may be androgen-receptor specific. Further
testing is warranted to determine the ability of these compounds to bind to the AR
in vitro, and their ability to act in an anti-androgenic mechanism, as is seen with
other plant-derived compounds like EGCG and atraric acid. These non-steroidal
compounds work by preventing translocation of the AR to the nucleus, and thus
preventing the transcriptionally active conformation of the AR from turning on
genes relevant to the proliferation and differentiation of prostate cancer. Because
antiandrogen therapies are often later converted by the body into androgen
receptor antagonists, resistance to antihormone therapy can be a major problem
for long-term treatment of prostate cancer. Should celosiadine A and B prove
effective as antiandrogens, they could add to the current armament of therapies a
structurally novel and natural aid to help promote prostate health.

EXPERIMENTAL SECTION
General Experimental Procedures: Silica gel (230−400 mesh, Sorbent
Technologies) and Sephadex LH-20 gel (Amersham Biosciences) were used for
column chromatography, and pre-coated silica gel GF254 plates (Whatman Ltd.,
Maidstone, England) were used for TLC analysis. Semi-preparative HPLC
separations were performed on a Hitachi Elite LaChrom system consisting of an
L2130 pump, an L36 2200 auto-sampler, an L-2455 diode array detector and a
Phenomenex Luna C18 column (250 ~ 10 mm, S-5 µm), all operated by EZChrom
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Elite software. The UV spectra were measured on a Shimadzu UV-2550
UV−visible spectrophotometer. All solvents were of ACS- or HPLC-grade and
were obtained from Sigma-Aldrich (St. Louis, MO, USA) through Wilkem
Scientific (Pawtucket, RI, USA). 1D and 2D NMR data were recorded on a Varian
500 MHz instrument with dimethyl sulfoxide-d6 as solvent and TMS as internal
standard. NOESY experiments were conducted using a three-pulse sequence with
a mixing time of 400 milliseconds and 700 milliseconds. 1D NOE experiments
were conducted with pulse width of 90 degrees, a relax delay of 1, 512 scans with
a mix time of 500 mms and a block size of 16. HRESIMS data were acquired
using an LTQ Orbitrap XL mass spectrometer (Thermo Scientific). Optical
rotations were measured on an Auto Pol III automatic polarimeter (Rudolph
Research, Flanders, NJ, USA) at room temperature. The IR spectra were recorded
on a Bruker Tensor 27 FT-IR and analyzed using OPUS Data Collection and
Analysis software.
Plant Material: Three kilos of the aerial portions of the Iresine celosia plant
were collected in Masaya, Nicaragua in September of 2008 and kindly provided to
our laboratory by Iresine International, Inc. (Miami, FL, USA). The plant was
authenticated by Edda Contreras (Iresine International, Inc., Miami, FL) and Mr.
Peter Morgan, Master Gardener (University of Rhode Island College of Pharmacy,
Kingston, RI), and a voucher specimen (16CK37-IRE21712H) has been deposited
at the University of Rhode Island, College of Pharmacy, Medicinal Plant
Greenhouse.
Extraction and Isolation: In order to reproduce the commercial formulation,
comprised of 30% ethanol, in the laboratory, air-dried aerial portions (2.0 kg) of
Iresine celosia were extracted by maceration with 30% ethanol (16 L, 3 times for
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7 days per time period of 21 days) at room temp. 9 L of the aqueous solution was
recovered and dried to 1.2 mL through rotary evaporation, and then extracted
successively with n-Hexanes (1.2 L, 3 times), ethyl acetate (1.2 L, 3 times), and nbutanol (1.2 L, 3 times) successively. The n-butanol fraction (8.93g) was purified
through gravity column chromatography using silica gel (CHCl3-MeOH, 19:1 v/v
to 1:1 v/v) to yield four major fractions (A-F). Fraction A was further purified
using Sephadex LH-20 eluted with MeOH affording four fractions (20B-G).
Fraction 20E was separated by semi-preparative HPLC, eluted with MeOH-H20
with 0.1% TFA (10:90 v/v to 95:5 v/v in 25 min, 2 mL/min) to yield compounds
7, 8, 9, and 11. Fraction 20F was similarly separated by semi-preparative HPLC,
eluted with MeOH-H20 with 0.1% TFA (10:90 v/v to 100:0 v/v in 30 min, 2.5
mL/min) to yield compounds 4 and 10. Fraction 20G was also separated by semipreparative HPLC, eluted with MeOH-H20 with 0.1% TFA (10:90 v/v to 95:5 v/v
in 25 min, 2 mL/min) to yield compounds 5 and 6. Fraction E was further
separated using Sephadex LH-20 eluted with MeOH to afford two main fractions
(24A and 24B). Fraction 24B was separated by semi-preparative HPLC, eluted
with MeOH-H20 (10:90 v/v to 100:0 v/v in 27 min, 3 mL/min) to yield
compounds 1, 2, and 3.
Compound (1): light yellow amorphous solid; [α]D20 = +3.4o (MeOH); IR
vmax 3380, 1700, 1600 cm–1; 1H and 13C NMR data, see Table 1; HRESIMS m/z
242.1500 [M+H]+ (calcd C11H19N3O3, for 242.1499).
Compound (2): a light yellow powder; [α]D20 = +10o (MeOH); IR vmax
3380, 1700, 1600 cm–1; 1H and 13C NMR data, see Table 5; C11H19N3O2 as
determined by HRESIMS at m/z 226.1547, [M+H]+ (calcd C11H19N3O2, for
226.155).
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Compound (3): 1H and 13C NMR data, see Table 6 and were compared
with previously reported values in the literature [27].
In silico Molecular Modeling Study: Crystal structures of the wild type
human Androgen Receptors (PDB ID: 2YHD), the T877A mutant human AR
(PDB ID: 1I37) and the H874Y mutant human AR (PDB ID: 2Q7L) were
obtained from the Protein Data Bank (PDB) as a template for docking of
compounds isolated from Iresine celosia [28]. Receptor macromolecules were
checked for completeness and accuracy by overlapping with other known,
reported androgen receptor crystal structures using Chimera [29]. Structures were
cleaned and split from ligands with which they were crystalized, and residual
water removed using the Accelrys Discovery Studio 3.5. Autodock Tools (version
1.5.4) was used to add all hydrogens, including non-polar, Kollman charges, and
solvation parameters [30]. After adding charges, all non-polar hydrogens were
merged. Autogrid, a program included within Autodock Tools, was used to
generate grid map size parameters, which were then incorporated into
configuration files used for docking in Autodock Vina, with grid coordinates
centered on the known ligand binding domain. Grid box dimensions were set to
24.051 x 1.363 x 5.150, adjusting the spacing between the grid points to be 1Å.
ChemDraw3D was used to create protein databank (.pdb) files for all
compounds used in docking experiments. Ligands were further prepared, with
Gasteiger charges assigned, all non-polar hydrogens merged, and the number of
torsions set using Autodock Tools. All bond rotations for ligands were
automatically set in ADT using the Lamarckian generic algorithm (LGA). The
exhaustiveness number was set to 16 and the solutions for each docked ligand
were evaluated through analysis of the text files containing binding affinity data
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(kcal/mol) and route mean square deviations (RMSDs), and inspection of .pdbqt
files to assess physical configuration of docked molecules and reproducibility
among docking modes. Batch files used to script automated docking procedures
were prepared using the text editing program TextWrangler. Docking was
conducted using Autodock Vina.
Known non-androgen receptor binders stigmasterol and beta-sitosterol
were used as negative controls, while natural androgen receptor ligands
testosterone and 5α-dihydrotestosterone (5α-DHT) were used as positive controls
for docking studies [31]. In addition, a set of natural product structures associated
with prostate health, including apigenin, emodin, baicalein, genistein, icaritin,
xanthohumol, and known AR-binders atraric acid and EGCG were used as a set
for comparison [22].
Prostate Cancer Assay:
The cellular cytotoxicity of the Iresine celosia extract and isolated
compounds celosiadine A and B was evaluated using the Alamar blue assay
(Invitrogen, Burlington, ON) as per manufacturer’s instructions. The Alamar blue
assay measures cellular metabolic activity (and thus cellular viability) via the
reduction of a nonfluorescent redox indicator to a fluorescent product by viable
cells. The reduction of Alamar blue reagent by Iresine celosia extract-treated,
compound (1)-treated, and compound (2)-treated cells were compared to that of
vehicle control-treated cells.
Human LNCaP and PC3 prostate adenocarcinoma cells (ATCC, Manassas,
VA) were cultured on 100 mm plastic tissue culture dishes (Falcon, Mississauga,
ON) in alpha-MEM supplemented with 1% (v/v) antibiotic/antimycotic
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(Invitrogen, Burlington, ON) and 10% (v/v) fetal clone III bovine serum
(Hyclone/VWR Canlab, Mississauga, ON) and were grown at 37°C in 5% CO2.
Compounds (1) and (2) were tested at 12.5, 25, and 50 µM concentrations.
The butanol extract was tested at the 50 and 250 ppm concentration. Exposure
time was for 6 hours and 24 hours.
The cellular cytotoxicity of Iresine celosia extract was evaluated using the
Alamar blue assay (Invitrogen, Burlington, ON) as per manufacturer’s
instructions. The Alamar blue assay measures cellular metabolic activity (and thus
cellular viability) via the reduction of a non-fluorescent redox indicator to a
fluorescent product by viable cells. The reduction of Alamar blue reagent by the
individual compounds and extract-treated and fraction-treated cells was compared
to that of vehicle control-treated cells.

43

Acknowledgement. This material is based upon work conducted at a research
facility at the University of Rhode Island supported in part by the National
Science Foundation EPSCoR Cooperative Agreement #EPS-1004057. In addition,
the authors also wish to thank Jason Ramsay and Justin Stroh at Pfizer, Groton,
CT for the use of their HRESIMS.

ASSOCIATED CONTENT
Supporting information. The 1D and 2D NMR spectra and mass spectrometry
data for compounds (1) and (2) are available free of charge via the Internet at
http://pubs.acs.org.

AUTHOR INFORMATION
Corresponding Author
*Tel.: 401-874-9367, Fax: 401-874-5787, E-mail: nseeram@uri.edu.

44

REFERENCES
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.

18.
19.

Levin, R.M. and A.K. Das, A scientific basis for the therapeutic effects of
Pygeum africanum and Serenoa repens. Urol Res, 2000. 28(3): p. 201-9.
Davy, H., Sir, 1778-1829. , Collected works of Sir Humphry Davy. Edited
by his brother John Davy. With a new introd. by Robert Siegfried. 1972,
New York: Johnson Reprint Corp.
United States Department of Agriculture, N.R.C.S. Plants Database.
[cited 2013 2013 February 1]; Available from:
http://plants.usda.gov/java/nameSearch.
Daniel F. Austin, P.N.H., Florida Ethnobotany. 2004: CRC Press.
Standley, P.C., Trees and Shrubs of Mexico, Part 2. 1922, Government
Printing Office: Washington, DC.
Djerassi, C., et al. Iresin (Part 2): A New Fundamental Sesquiterpene
Skeleton. 79: p. 3528-3534.
Djerassi, C., et al. Iresin (Part 3): Reactions of the Glycol Stem. J. Am.
Chem. Soc., 1958. 80: p. 1972-1978.
Djerassi, C., et al. Iresin Part 5 - Complete Structure and Absolute
Configuration. Tetrahedron, 1959. 7: p. 37-46.
Djerassi, C., et al., The Isolation of Iresin, a New Sesquiterpene Lactone. J.
Am. Chem. Soc., 1953. 76: p. 2966-2968.
Crabbe, P.L., Djerassi, C., Djerassi, C., et al. Naturally occurring oxygen
heterocyclics. III. The structure of the isoflavone tlatlancuayin. Journal of
the American Chemical Society, 1958. 80: p. 5258-63.
Djerassi, C., et al., The Structure and Absolute Configuration of Iresin. J.
Nat. Prod., 1958. 80: p. 2593.
Rios, M.Y. and L.A. Berber, 1H and 13C assignments of three new
drimenes from Iresine diffusa Humb. & Bonpl. ex Willd. Magnetic
resonance in chemistry : MRC, 2005. 43(4): p. 339-42.
Berlinck, R.G.S., Natural guanidine derivatives. Natural Product Reports,
1996. 13(5): p. 377-409.
Berlinck, R.G.S., A.E. Trindade-Silva, and M.F.C. Santos, The chemistry
and biology of organic guanidine derivatives. Natural Product Reports,
2012. 29(12): p. 1382-1406.
Cong, H., et al., Guanidine Alkaloids from Plumbago zeylanica. J. Nat.
Prod. 2013. 76(7): p. 1351-1357.
Bhatnagar A., S.P.K., Kumar N., A Review on “Imidazoles”: Their
Chemistry and Pharmacological Potentials. International Journal of
PharmTech Research, 2011. 3(1): p. 268-282.
Papaioannou, M., et al., The natural compound atraric acid is an
antagonist of the human androgen receptor inhibiting cellular
invasiveness and prostate cancer cell growth. J Cell Mol Med, 2009.
13(8b): p. 2210-23.
Siddiqui, I.A., Green tea polyphenol EGCG blunts androgen receptor
function in prostate cancer. FASEB J., 2011. 25(4): p. 1198–1207.
Roell, D., Baniahmad A., The natural compounds atraric acid and Nbutylbenzene-sulfonamide as antagonists of the human androgen receptor
and inhibitors of prostate cancer cell growth. Molecular and Cellular
Endocrinology, 2011. 332 p. 1–8.

45

20.
21.

22.

23.
24.
25.
26.
27.
28.
29.
30.
31.

Askew, E.B., et al., Modulation of androgen receptor activation function 2
by testosterone and dihydrotestosterone. J Biol Chem, 2007. 282(35): p.
25801-16.
Sack, J.S., et al., Crystallographic structures of the ligand-binding
domains of the androgen receptor and its T877A mutant complexed with
the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A, 2001.
98(9): p. 4904-9.
Azimi, H., et al., A review of animal and human studies for management of
benign prostatic hyperplasia with natural products: perspective of new
pharmacological agents. Inflamm Allergy Drug Targets, 2012. 11(3): p.
207-21.
Reuter, G., Biosynthesis of Pharmacologically active guanidine derivatives
with isoprenoid carbon chains. Planta Medica, 1965. 13(4): p. 494.
Reuter, G., Biosynthesis of terpenoid guanidine. Geologie und Biologie,
1966. 3: p. 617-621.
Reuter, G., Barthel, A., Guanidinoacetic acid as a precursor of galegine in
Galega officinalis. . Pharmazie, 1967. 22(5): p. 262.
Barthel, A., Reuter, G., Biochemistry and Physiology of isoprenoid
guanidines, especially (4-hydroxy-3-methyl-2-buten-1-yl) guanidine in
Galega officinalis. Pharmazie, 1968. 23(1): p. 26-33.
Wang, W. et al., Chemical constituents in aerial parts of biebersteinia
heterostemon maxim. Nat. Prod. Res. Dev., 2009. 21: p. 199-202.
Berman, H.M., et al., The Protein Data Bank. Nucleic Acids Res, 2000.
28(1): p. 235-42.
Pettersen, E.F., et al., UCSF Chimera--a visualization system for
exploratory research and analysis. J Comput Chem, 2004. 25(13): p.
1605-12.
Morris, G.M., et al., AutoDock4 and AutoDockTools4: Automated docking
with selective receptor flexibility. J Comput Chem, 2009. 30(16): p. 278591.
Fang, H., et al., Study of 202 natural, synthetic, and environmental
chemicals for binding to the androgen receptor. Chem Res Toxicol, 2003.
16(10): p. 1338-58.

46

High-Performance Liquid Chromatography
Characterization of New, Species-Specific Guanidine
Alkaloid Marker Compounds in the Botanical Dietary
Supplement Iresine celosia
Caroline Killian, Tao Yuan, Liya Li, and Navindra P. Seeram*

Bioactive Botanical Research Laboratory, Department of Biomedical and
Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island,
Kingston, Rhode Island 02881, United States
*Corresponding author. Tel.: 401-874-9367, Fax: 401-874-5787, E-mail:
nseeram@uri.edu

This chapter is written in the style of the Pharmaceutical Biology journal.

47

Abstract
Iresine celosia is the sole active ingredient of the Odyliresin™ dietary supplement
formulation currently marketed to humans worldwide as an antioxidant for the
promotion of prostate health. Like many botanical dietary supplements, the
ingredient lacks authentication methods to characterize its phytochemistry. This
work presents an analytical method for high-performance liquid chromatography
(HPLC) and development of an analytical finger print profile that can be used to
standardize the Iresine celosia botanical extract. Of the eleven compounds
isolated from this plant and identified on the fingerprint chromatogram, the
appearance of two new cyclic guanidine alkaloid compounds unique to this
botanical specimen are among the most abundant and serve as important marker
compounds for the extract. In this study, a method for the quantitative analysis of
the two new guanidine alkaloids (GAs) present in the Iresine celosia botanical
extract formulation was developed, celosiadine A and B, or compounds (1) and
(2) respectively. A lab-produced formulation of the aerial plant material was
extracted with 30% ethanol and subject to sequential liquid-liquid partitioning
with n-hexanes, ethyl acetate, and n-butanol. Samples of the manufacturer’s
Odyliresin™ formulation were also subject to the same sequential partitioning.
Butanol fractions, Lab-bu and Odyli-bu, were analyzed and the GAs quantified by
HPLC. Calibration curves were tested in triplicate and showed good linearity (r^2
> 0.99) within the tested ranges and the concentrations of these compounds in the
extracts were quantified based on the standard curves. The Lab-bu fraction
appeared to have almost ten times as much of compounds (1) and (2) as the Odylibu fraction, with compound (1) comprising 0.032% of the Lab-bu formulation,
and 0.0032% of the Odyli-bu formulation, and compound (2) comprising 0.4% of
the Lab-bu formulation, and 0.04% of the Odyli-bu formulation respectively.
Identification of relevant marker compounds, analytical method development, and
analytical finger print profiling can help to address the deficiency of knowledge
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needed for botanical dietary supplement formulations like Odyliresin™ to achieve
a level of quality production and safe use.

Introduction
Analytical method development for botanicals used by humans in the form
of dietary supplements has been identified as an important area of research by a
variety of regulatory bodies, including the U.S. Congress, National Institutes of
Health (NIH), Food and Drug Administration (FDA), National Institute of
Standards and Technology (NIST), clinical researchers, including those seeking
funding from the National Center for Complementary and Alternative Medicines
(NCCAM), product manufacturers, and other industry stakeholders who seek to
ensure that consumers have access to quality dietary supplement products [56-58].
Current good manufacturing practice (cGMP) regulations for dietary supplements
require manufacturers to demonstrate that “specifications are met for the identity,
purity, strength, and composition of the dietary supplements” [59]. However,
regulations do not instruct manufacturers about particular analytical methods
required to meet these stipulations. Rather, each botanical component requires a
specific, scientifically valid authentication method in order to provide the
necessary proof to comply with regulations.
In particular, analytical separation techniques like high performance liquid
chromatography (HPLC) currently provide the most reliable and applicable
authentication methods for botanicals. To accomplish this, however, it is
necessary to isolate and identify selected “marker” compounds that make up an
analytical fingerprint that is distinct for the selected species. Especially for less
widely known botanicals, this work requires extensive phytochemical
investigation of the plant, and usually includes the development of tailored
isolation schemes, compound purification, and structure elucidation experiments,
alongside the development of analytical methodology fitting to the botanical
specimen to standardize extracts.
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Iresine celosia is a member of the Amaranthaceae family. The plant is
native to Central America, Mexico and southern portions of the United States like
Texas and Florida [60]. It has a history of use as a traditional medicine by the
Mayan people of Chiapas Mexico, who used this plant for a variety of conditions,
among them malaria, gonorrhea, and dropsy [35, 36, 38-40, 42, 43, 61]. To them,
it was known as tlatlancuaya, although this name has been used to describe other
botanical medicines in the region. In addition, the plant also has over 27 botanical
synonyms [34-36, 38, 60]. Because of the many names ascribed to the plant, there
is added utility to the development of chemical reference standards as this
information can also be used in the taxonomical identification of the plant and
products made therefrom.
Today, Iresine celosia is best known for its use as the sole active
ingredient in the Odyliresin™ Antioxidant botanical formulation, used for the
promotion of prostate health in humans [33]. The product is produced in a 30%
ethanolic aqueous extract of the aerial portions of the plant. Although produced on
small (1L or less) scale in single batches, cGMP regulations apply also to small
scale manufacturers of dietary supplements like the makers of the Odyliresin™
Antioxidant botanical formulation. This work represents the first phytochemical
investigation of this formulation resulting in the identification of marker
compounds and their use in analytical profiling of the formulation.
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Materials and Methods
Plant Material
Aerial portions of the Iresine celosia plant were collected in Masaya,
Nicaragua in September of 2008 and kindly provided to our laboratory by Iresine
International, Inc. (Miami, FL, USA). The plant was authenticated by Edda
Contreras (Iresine International, Inc., Miami, FL) and Mr. Peter Morgan, Master
Gardener (University of Rhode Island College of Pharmacy, Kingston, RI), and a
voucher specimen (16CK37-IRE21712H) has been deposited at the University of
Rhode Island, College of Pharmacy, Medicinal Plant Greenhouse. In addition,
three Odyliresin™ Antioxidant, 50 ml dispenser bottles were provided by the
manufacturers from one batch of product, the only available at the time.

HPLC Conditions
Semi-preparative HPLC separations were performed on a Hitachi Elite
LaChrom system consisting of an L2130 pump, an L36 2200 auto-sampler, an L2455 diode array detector and a Phenomenex Luna C18 column (250 ~ 10 mm, S5 µm), all operated by EZChrom Elite software. The UV spectra were measured
on a Shimadzu UV-2550 UV−visible spectrophotometer. All solvents were of
ACS- or HPLC-grade and were obtained from Sigma-Aldrich (St. Louis, MO,
USA) through Wilkem Scientific (Pawtucket, RI, USA). A linear gradient
chromatographic technique was used at room temperature with the following
solvent system: solvent A = 0.1% trifluoroacetic acid with filtered, deionized
water; solvent B = methanol; starting at 10% A:90% B and rose via a gradient to
40% A:60% B at 30 minutes. From 30 min to 35 min, solvent A 0%:100% B and
continued to 40 minutes. From 40 to 42 minutes, 10% A:90% B and run to 52
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minutes. The flow rate was 0.75 mL/min throughout. Detection was monitored via
diode array detector between 200 nm - 520 nm wavelength. All HPLC-UV
analyses were carried out with 15uL injection volumes. Compounds (1) and (2)
were monitored at 212 nm. In addition, compound (3) was monitored at 210, (4) at
256 nm, (8) at 264 nm, and (10) at 260 nm. The concentration of these compounds
was quantified based on the standard curves.

Preparation of extracts
For analysis by HPLC
Lab-Neat formulation: Following manufacturer’s production instructions,
a 30% ethanolic extract (16 liters) was added to cover and saturate 2 kilos of dried
plant material, and set aside for three weeks with occasional (apx. every 72 hours)
stirring. 9 liters of the ethanolic extract were recovered, dried to 1.2 L through in
vacuo, and sequentially partitioned with n-hexanes, ethyl acetate and n-butanol.
Odlyi-Neat, Manufacturer’s formulation: 15 mL of the formulation neat,
with ethanol removed and dried down to 10 mL, was subject to liquid-liquid
partitioning sequentially with n-hexanes, ethyl acetate and n-butanol. The
resultant n-butanol fraction was dried in vacuo and resulted in a 96.4 mg residue.
Dried residues of these products were weighed and reconstituted to the
appropriate concentration using HPLC-grade methanol.
Lab-bu and Odyli-bu test samples were generated by bringing up from dry
weight in 30% HPLC-grade methanol and 70% DI-water a 250 mg/mL stock
concentration, from which 150, 100, 75, 50, 25, and 10 mg/mL concentrations
were derived. In addition, 500 mg/mL concentrations were made separately and
also tested. Samples were centrifuged prior to injection in HPLC, and all samples
were injected with a 15 µL injection volume. Each sample was injected in
triplicate and a linear calibration curves (r2 = 0.99) constructed by plotting the
mean peak area percentage against concentration. The presence of compounds (1)
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and (2) was determined with the use of 5-point calibration curves for standard
compounds. Stock solutions were stored at 4°C (see Figure 37 -47).

Identification of the isolated compounds
For isolation and identification of standard compounds
Lab-Neat formulation was prepared as described above. The butanolsoluble fraction (Lab-Butanol) was subjected to silica gel gravity column
chromatography and eluted with chloroform and methanol (19:1 CHCl3:MeOH to
1:1 CHCl3:MeOH), affording four major fractions. Fraction E resulting from 5:1
CHCl3:MeOH elution was further purified using Sephadex LH-20 resin eluted
with methanol. Fractions were evaluated using analytical HPLC.
Semi-preparative HPLC afforded the isolation of marker compounds (1)
and (2). In addition, additional purification afforded compounds 3-11. Detailed
analysis of the 1D and 2D NMR data allowed for the construction of the structure
of Compound (1) and (2). Compounds 3-11 were identified based on 1H spectra
and 13C and comparison with prior literature [62]. Details on this work are
reported elsewhere (see Chapter 2).
Standard Preparation
Stock solutions of the isolated GA standards, compound (1) and compound
(2), were prepared as follows: 1-3 mg standard was accurately weighed. Next, a
mixture of 30% HPLC-grade methanol and 70% filtered, deionized water was
added and the solution was serial diluted to volume with the same solvent to
afford samples of 1.00, 0.500, 0.250, 0.125, 0.0625, 0.03125, and 0.015625
mg/mL concentrations respectively. Each sample was injected in triplicate and a
linear five-point calibration curve (r2 = 0.99) was constructed by plotting the mean
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peak area percentage against concentration. Each stock solution was stored at 4°C.
In addition, compounds (3), (4), (8), and (10) were also tested though results were
not reproduced in triplicate. Stock solutions of these compounds were prepared at
concentrations relevant to each compound, as follows: (3) at 3.5, 1.75, 0.875, and
0.4375 mg/mL; (4) at 1.9, 0.950, 0.475, 0.238, and 0.119 mg/mL; (8) at 0.4, 0.2,
0.1, 0.05, 0.025 mg/mL; (10) at 0.55, 0.275, 0.138 mg/mL (see Figures 42-47).

Detection Limit and Quantitation Limit
The limits of detection (LOD) and quantitation (LOQ) were determined
based on the standard deviation of the response and the slope, which is one of the
LOD and LOQ measurements in the ICH guidelines [63]. The LOD and LOQ
were calculated as described as follows:

LOD (µg mL−1) = 3.3 σ/S
LOQ (µg mL−1) = 10 σ/S

where σ = the standard deviation of the response, and
S = the slope of the calibration curve.

To calculate σ, a calibration curve of the sample with compound that had a
concentration similar to the LOD, LOQ was studied. The standard deviation of the
y-intercepts of the regression lines was used as σ. For compound (1), LOD was
calculated as 0.13 mg/mL, and LOQ as 0.39 mg/mL (see Table 11). For
compound (2), LOD was calculated as 0.18 mg/mL and LOQ as 0.56 mg/mL.
LOD and LOQ were not determined for compounds (3), (4), (8), and (10).
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Results and Discussion
In the current study, a method was developed to analyze the content of the
GAs, compound (1) and (2), novel botanical identifiers and potentially the healthrelevant principles of the Iresine celosia botanical formulation. Initially, four
samples were analyzed: Lab-Neat, a lab-generated 30% ethanolic extract, OdyliNeat, the manufacturer's own 30% ethanolic extract, and butanol partitions of
these fractions, Lab-Butanol and Odyli-Butanol. These samples were analyzed
and the GAs quantified by HPLC-DAD. However, because 30% ethanolic crude
extract's marker compounds were well below limits of detection in the form sold
to patients, and saturated when the material was dried and brought up to detectable
concentrations, further purification was required to standardize the extracts.
Further purification steps are standard when dealing with complex mixtures, and
in this case partitioning with hexane and ethyl acetate and finally butanol was
required. With these defatting steps accomplished, the butanol fractions were
analyzed for their presence of the two marker compounds.
The content of guanidine alkaloids within the complex botanical
formulation of Iresine celosia is quite small. Compound (1) comprised 0.032% by
weight of the Lab-bu formulation, and 0.0032% of the Odyli-bu formulation, and
compound (2) comprised 0.4% of the Lab-bu formulation, and 0.04% of the
Odyli-bu formulation. The Lab-bu fraction appeared to have almost ten times as
much of compounds (1) and (2) as did the Odyli-bu fraction. Lab-bu fraction at 50
mg/mL concentration contained amounts of compounds (1) and (2) comparable to
the Odyli-bu fraction at 500 mg/mL (see tables 12, 13, 18, 19).
Additionally, compounds (3), (4), (8), and (10) hydroxygalegine, uracil,
2’deoxythymidine, and anisic acid respectively were also quantified in the Lab-bu
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formulation, but were below the limits of detection for the Odyli-bu formulation
(see Figures 50-53). Compound (3) comprised 0.002% by weight of the Lab-bu
formulation, compound (4) comprised 0.004%, compound (8) comprised
0.0008%, and compound (10) comprised 0.001% of the Lab-bu formulation.
The lack of relevant marker compounds is said to be the major limiting
factor hindering the widespread adoption of quality control approaches for
botanical supplements [30]. To allow for documentation that products meet
manufacturer’s specifications and that products contain what their labels declare,
analytical method development is needed. These methods define a level of quality
that can be verified with each batch production.
Most notable among the compounds isolated from the Odyliresin™
botanical formulation are two novel cyclic guanidine alkaloids unique to Iresine
celosia, the formulation’s sole component. The novelty of these molecules within
the botanical specimen, and the abundance with which they are found in the
formulation among other reasons allow for the use of these compounds as good
markers to identify and authenticate both the Iresine celosia plant and the
Odyliresin™ formulation. In addition, while guanidine alkaloids are found in a
handful of plant species, only one other plant is known to possess 2-substittued
imidazolines, making them structurally novel identifiers [64-70]. The
Odyliresin™ botanical formulation also possess a number of nucleosides (among
them, 2’deoxy-uridine, 2’deoxy-thymidine, uracil and adenine), along with some
additional small molecule structures (3-indole-carboxyllic acid, anisic acid, and
phenylacetamide).
Biologically active ingredients that represent the “health-relevant principle
components” of the formulation are also preferred as marker compounds [30],
although this point is elsewhere contested as unnecessary [56]. In silico screening
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suggests that the GA marker compounds may also play a role in the biological
activity of the extract when used for promotion of prostate health. Docking
experiments revealed that the new compounds bind to the human androgen
receptor, both wild type and mutant forms relevant in prostate-cancer progression.
Further testing in LNCaP AR-sensitive cell lines showed favorable activity of the
compounds in the 12.5-50 µM range, while leaving PC3, AR-independent cell
lines otherwise unchanged (see Chapter 2). Like other botanical structures EGCG
and atraric acid, these compounds may also act as anti-androgens. Thus, due to
their novelty and potential health-relevant component for the species in question,
and the relative abundance with which they are found in the plant, these
compounds can be used as unique identifiers to the botanical specimen, and could
potentially be used to quantify the potency of what is likely the health-relevant
principle within the extract.
The isolation of single active principles from botanical natural product
dietary supplements like the Odyliresin™ formulation of Iresine celosia will
allow for further evaluation of this formulation’s safety when used in humans and
efficacy when used as a remedy to promote health of the prostate, and
authentication of the formulation’s ingredients using the presence of chemical
marker compounds in the commercial product.
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Perspective on the Regulatory and Scientific Evaluation of
Botanical Dietary Supplement Safety

Abstract
The release of the Draft Guidance for Industry, Dietary Supplements: New
Dietary Ingredient Notification and Related Issues in July 2011 marked a turning
point for the dietary supplement industry. The document outlined
recommendations for the new dietary ingredient (NDI) submission process,
including a battery of pre-clinical tests required for submission prior to
introduction of a product into interstate commerce, and with it defined a level of
scientific testing heretofore unprecedented in the industry. As regulatory
requirements to provide extensive toxicological testing data on botanical dietary
supplements increase, without a corresponding increase in resources for
companies called upon to provide such data or for regulators of the industry, in
silico screening of natural product structures presents a resource-conscious
strategy that could play a role in the risk assessment of botanical ingredients.
Based on knowledge of structural features of compounds from botanical natural
products known to be toxic, new compounds for which little or no toxicological
data exists could be screened for similar functional groups and structural alerts
generated. This information could then be used to guide chemical and
toxicological testing resources to where they are needed most, as well as
streamline the regulatory review of these products. In this work, a review of
regulation of the dietary supplement industry since 1994 was conducted, with
emphasis on the development of current thinking on the interpretation of the NDI
notification system. A survey of use of in silico methodology for chemical risk
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assessment is also discussed, as well as how such a method may be applied to
botanical natural product structures in particular.

The Regulatory Landscape
In the U.S. marketplace alone, consumers continue to spend increasing
amounts on botanical dietary supplements, from $3 billion in 1996 to $5 billion in
2010 [71]. More widespread use of herbal products has resulted in increased
attention to the safety of these products by consumers in the market place,
manufacturers, and regulatory bodies. The passage of the Dietary Supplement
Health and Education Act (DSHEA) in October 1994 authorized the U.S. Food
and Drug Administration (FDA) to extend its authority to monitor and evaluate
the safety, quality and labeling of dietary supplements. Core elements of the
amendment to the Food, Drug and Cosmetic Act resulting from the passage of
DSHEA include enhanced reach of the FDA to monitor dietary safety and quality,
require pre-market notification, conduct labeling oversight, and post-market
surveillance. Of these, the ability to monitor safety and quality through the use of
pre-market notification has caused the greatest difficulty in compliance for
botanical dietary supplements manufacturers.
To specify, monitoring dietary supplement safety and quality includes the
authority to impose an immediate ban of products that pose an imminent hazard,
impose requirements for Good Manufacturing Principles (GMP), inspect facilities,
and collect adverse event reports associated with dietary supplement use.
Instituting pre-market notification requirements works to prohibit any new dietary
ingredient (NDI) for which there is inadequate information from entrance into
interstate commerce. For those ingredients that are considered new, manufacturers

65

must provide reasonable assurance that it does not present a significant or
unreasonable risk of illness or injury. However, debate over what constitutes a
new dietary ingredient and the information needed to provide such a reasonable
assurance is a current point of discussion among manufacturers, trade groups, and
regulators of dietary supplements.
The dietary supplement industry has been operating under the New Dietary
Ingredient (NDI) submission process since the 1994 passage of DSHEA. When
DSHEA was signed into law, the legislation modified the Federal Food, Drug and
Cosmetic Act (FDCA) by adding section 413, which outlines requirements to
market a new dietary ingredient or a dietary supplement that includes a new
dietary ingredient [72, 73]. The term new dietary ingredient is defined as “a
dietary ingredient that was not marketed in the United States before October 15,
1994 and does not include any dietary ingredient which was marketed in the
United States before October 15” [74]. Specifically, this statute requires the
manufacturer or distributor of a NDI, or of the dietary supplement that contains
the NDI, to submit a premarket notification to FDA at least 75 days before
introducing the supplement into interstate commerce or delivering it for
introduction into interstate commerce, unless the NDI and any other dietary
ingredients in the dietary supplement “have been present in the food supply as an
article used for food in a form in which the food has not been chemically altered”
[75]. Providing proof for this claim, however, is quite specific. Sales records,
manufacturing records, commercial invoices, magazine advertisements, mail order
catalogues, and sales brochures are all acceptable forms of evidence; affidavits
alone are not [76]. Supposing these forms of proof can be supplied, they apply
only if the currently marketed dietary supplement formulation has been in no way
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chemically altered from the product as it existed prior to 1994. In addition,
because no official list of dietary ingredients that can be considered
“grandfathered” is recognized by regulatory authorities, it is rarely the case that
supplement manufacturers are able to prove that their product is not new, even if it
has a history of use as a traditional botanical medicine. Thus, most botanical
dietary supplements are subject to the NDI submission process.
For those dietary supplements that must complete the NDI submission
process, a new level of scientific rigor and premarket testing is outlined in the
Draft Guidance document, heretofore unprecedented in the industry. Although the
NDI submission provision has existed since the 1994 passage of DSHEA, recent
debate in the dietary supplement community has centered around whether or not
recent enforcement efforts have added greater rigor to the provision than was
originally intended in the law. This point of debate matters to manufacturers of
dietary supplements because the level of scientific testing outlined in recent
legislation and regulatory guidance documents rises to a level of rigor that may
not be appropriate for dietary supplements, and so cost-prohibitive as to put many
dietary supplement companies out of business.
It has been pointed out elsewhere that the provisions required for premarket
testing of dietary supplements and the wording copies almost directly from
provisions outlined for the testing of food additives [77]. This is a significant
point of contention, since the passage of DSHEA can be viewed historically as a
battle between regulators and supplement manufacturers about whether or not
dietary supplements could be considered and thus recalled as illegal food additives
(for which prior market testing must demonstrate the safety with scientific
evidence) or their own distinct regulatory class, neither food, food additive nor
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drug, but dietary supplements (which do not require premarket proof of safety,
only a reasonable expectation of safety, which lays the burden of proof that a
product is unsafe upon regulators in order to issue a recall) [78]. Ultimately, the
view that dietary supplements were not food additives and did not require proof of
safety, but only a reasonable expectation of safety, carried the day and DSHEA
was written and passed to reflect this thinking. DSHEA specifically noted that
dietary supplements are not to be treated as food additives. This was pointed out
in the 1994 law because such testing is not necessarily appropriate for the
supplements being tested. Thus, an NDI Draft Guidance that has copied premarket testing provisions from food additive premarket safety testing guidance
documents would be out of line with DSHEA.
In addition, as the majority of the dietary supplement industry is comprised
of small companies, employing 20 or fewer, such testing may be cost prohibitive
[79]. Even if the industry were to comply by providing what amounts to millions
of dollars in pre-market chemical characterization and toxicological testing for
each new dietary ingredient brought to market, it is unclear that the regulatory
authorities have the manpower to cull and make use of the information submitted.
At the time of commentary on the NDI submission process in 1997, the agency
estimated the number of NDI notifications that would be filed annually would be
between zero and 12 [80]. However, the fact that there are “only” 700 submissions
annually even though there are an estimated 55,600 dietary supplement products
on the market is now a figure used as an indication that the industry has been lax
with compliance [81].
This change in agency thinking indicates that a shift has occurred toward a
more stringent NDI submission policy, requiring more scientific information prior
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to product launch. Helping manufacturers clear the hurdle of regulatory
compliance with an enhanced scientific framework may present a new area of
opportunity for contract laboratories, including natural products laboratories
housed in academia that specialize in analytical chemistry and pharmacology, and
are willing to work as contract laboratories under an academic umbrella.
Understanding the development of current thinking on the NDI provision may
help to clarify potential avenues whereby information required for NDI
submission, or what amounts to preclinical testing of botanicals, could be
accomplished in a cost-effective, resource-conscious manner.

A Reasonable Expectation of Safety
In September 1997, FDA issued a Final Rule on Premarket Notification for
a New Dietary ingredient [82], to clarify the “procedure by which a manufacturer
or distributor of dietary supplements or of a new dietary ingredient is to submit
under the Food Drug and Cosmetic Act the information on which it has concluded
that a dietary supplement containing an NDI will reasonably be expected to be
safe” [83]. Although additional clarification is outlined in the rule, manufacturers
and distributors of dietary supplements still required guidance on a number of
issues related to new dietary ingredients and requirements for notification
submissions. On January 4, 2011, the Food Safety Modernization Act (FSMA)
was signed into law [84]. The legislation included in section 113 required that 180
days after enactment of FSMA, the FDA issue a guidance document on NDIs.
FSMA directed the guidance to include provisions that clarify when an ingredient
is considered an NDI and when the manufacturer or distributor of a dietary
ingredient is required to provide the required information under section 413 of the
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FDCA [85]. FSMA also directed FDA to include the evidence needed to
document the safety of NDIs as well as appropriate methods for establishing the
identity of NDI. On June 21, 2011, one of the original sponsors of DSHEA,
Senator Hatch (R-UT), alongside Senator Harkin (D-IA) submitted a letter to
Congress calling for the release of the guidance document to “provide clarity,
predictability, and certainty to dietary supplement manufacturers and the public on
FDA’s interpretation and expectation related to the marketing of NDIs.” In July
2011, the Draft Guidance for Industry: Dietary Supplements: New Dietary
Ingredient Notifications and Related Issues was released for public comment [86].
If FDA is able to meet all of its program priorities, a final NDI guidance is
anticipated for 2014 [87].
The draft guidance is presented in a question-and-answer format to help
industry determine when a dietary ingredient is new, deciding when premarket
safety notification is necessary, and what type of information is needed for a
complete notification. While the statement that any dietary ingredient marketed in
the US before October 15, 1994 is exempt from the need to file an NDI seems
straight forward enough, the information required to prove that a dietary
ingredient was marketed before that time is very specific. The dietary ingredient
must have (1) been sold or offered for sale (2) as a dietary supplement, in bulk as
a dietary ingredient for use in dietary supplements, or as an ingredient in a blend
or formulation of dietary ingredients for use in dietary supplements (3) in the
United States (4) before October 15, 1994, and (5) not have undergone any
changes in manufacturing processes that would alter the chemical composition of
the ingredient or (6) changed the composition of materials used to make the
ingredient [88]. To establish that marketing took place in the U.S., the identity
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(e.g., chemical or botanical name) and form (e.g. ground herb, water extract, oil)
of the marketed ingredient, and whether the ingredient was marketed as a dietary
ingredient or for some other purpose, must be included in the evidence used. Valid
forms of evidence include written business reports, promotional materials, or press
reports with a contemporaneous date prior to October 15, 1994. Sales records,
manufacturing records, commercial invoices, magazine advertisements, mail order
catalogues and sales brochures are all acceptable; affidavits alone are not. In short,
the requirements to prove that a dietary ingredient is “grandfathered”, and does
not require a NDI notification, is extensive and very difficult to achieve, thus
requiring that most dietary supplements on the market today submit NDI.
Within the new dietary ingredient notification, filers are asked to include
information that makes the case to the FDA that there exists for their products a
standard of safety, defined as a “reasonable certainty of no harm.” The NDI
Guidance states,
The NDI safety standard is different than the standard for food
additives, drugs, pesticides, and other FDA-regulated products.
Recommendations in guidance documents that are tailored to the safety
assessment needs of other FDA-regulated products may not always be
appropriate for dietary ingredients and dietary supplement…You should
use your own best judgment in compiling scientific evidence that
provides a basis to conclude that the NDI that is the subject of your
notification will reasonably be expected to be safe when used under the
conditions recommended or suggested in the labeling of the dietary
supplement in the notification….You must provide the information that
forms the basis on which you have concluded that a dietary supplement
containing the NDI will reasonably be expected to be safe under the
supplement's labeled conditions of use (21 U.S.C. 350b(a)(2)). In
general, this information should include an adequate history of safe use,
safety studies, or both [88].
This “reasonable expectation of safety” is phrased in the FDCA Sec 402(f)(1)(B)
as a “reasonable assurance that such (an) ingredient does not present a significant
or unreasonable risk of illness or injury.”
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In outlining what sorts of information may be used in the NDI submission in
order to reach such a conclusion, the draft guidance introduces a scientific
framework, involving animal and human safety studies that are required when
history of use data and literature are inadequate [89]. These include an extensive
battery of toxicological testing used in the submission of new drug applications.
For a botanical supplement like Iresine celosia, the NDI is intended for daily
chronic use, and has a documented history of safe intermittent use, and the
proposed use of the NDI leads to intake levels that are the same as or less than the
levels consumed historically, the following types of data are recommended [90]:
(1) A three-study genetic toxicity (gentox) battery (bacterial
mutagenesis, in vitro cytogenetics, and in vivo mammalian test)
that includes a test for gene mutations in bacteria, either an in
vitro mouse lymphoma thymidine kinase+/- gene mutation
assay (preferred) or another suitable in vitro test with
cytogenetic evaluation of chromosomal damage using
mammalian cells, and an in vivo test for chromosomal damage
using mammalian hematopoietic cells;
(2) a 14-day range-finding oral study to establish a maximum
tolerated dose (MTD) in an appropriate animal model;
(3) a 90-day sub-chronic oral study in the same species as the
range-finding study to establish an MTD and a No Observed
Adverse Effect Level (NOAEL) for use in calculating the
margin of safety;
(4) a multi-generation rodent reproductive study (minimum
two generations); and
(5) a teratology study (rodent or non-rodent);
except that the latter two studies are not needed if the product
is labeled as not for use by women of childbearing age,
pregnant or lactating women, and children 13 and younger.
The cost of this battery of tests was calculated at a presentation by
international analytical testing lab firm Eurofins Scientific Incorporated in
collaboration with Spheris Incorporated on December 12, 2011 at the Food and
Drug Law Institute in Washington D.C. The findings are summarized in Tables
20-21. For a botanical dietary supplement like Iresine celosia with only one new
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dietary ingredient, supposing they are able to prove their historical use, estimates
range anywhere between $573,310 - $690,600 for intermittent use, and
$2,198,310 - $2,815,600 for chronic use. If they are unable to prove their
historical use, testing costs can range anywhere between $2,758,310 - $3,382,500.
These numbers represent starting points, of course, as additional testing may be
needed (see Table 20-21). The Draft Guidance also goes on to mention that,
“based on the nature of the NDI and the results of other testing special studies
(e.g., carcinogenicity, ADME) may be needed to provide a reasonable expectation
of safety. Other non-clinical studies to assess immunotixicity and neurotoxicity
should be conducted on a case-by-case basis, as appropriate.”
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Table 20:

Table 21:
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Currently, funding to conduct studies to evaluate the safety and efficacy of
dietary supplements is extremely limited. “It is impractical to think that any
government agency, institute, or private organization could provide sufficient
funds to adequately test the safety of tens of thousands of dietary supplement
products often marketed in combinations that may change in formulation from
year to year” [91]. The burden to conduct such testing has fallen to dietary
supplement companies. Those who cannot afford the extensive toxicological
testing outlined in the NDI may be forced out of business. In addition, regulators
do not have the manpower needed to sift through these documents and
toxicological testing results, even should companies be able to afford them.
Nevertheless, in spite of historical use and a generally accepted perception
that “natural” equates to safe, it is true that some natural product preparations
possess compounds that are known to be harmful when ingested by humans at
higher dosages, when taken over longer periods of time than is appropriate
(exposure), when taken in combination with prescription drugs (herb-drug
interactions), or used by certain high-risk patient populations (i.e., those with
compromised kidney and liver function) [92, 93]. Thus, the challenge remains, to
evaluate the safety of botanicals and preparations prior to introduction to interstate
commerce, to remain conscious of resources available to manufacturers and
regulators of dietary supplements, to test botanicals within a framework true to the
intent of DSHEA, and to use best judgment to support a reasonable expectation of
safety.
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Understanding the Risk Profiles Presented by Herbal Medicines:
A Question for Pharmacognosy
While it is true that “natural” does not equate to safe, it is also true that the
toxicity profiles of herbal medicines differ from those presented by toxic
chemicals, food additives and synthetic pharmaceutical compounds. For this
reason, they are and should continue to be regulated accordingly. When data was
evaluated from 55 countries between 1968-1997 was evaluated, analysis published
in the British Medical Journal noted that adverse events from herbal remedies
“amount to only a tiny fraction of adverse events associated with conventional
drugs held in the same (WHO) database” [11, 94]. Most of our risk profiling and
test parameters concerning compounds we ingest grow out of the pharmaceutical
paradigm that tests single molecular entities with potent and specific biological
effects. However, herbals present a very different risk profile, both due to their
dosing and due to specific presence or absence of structural features and
functional groups. One major reason the safety profiles of dietary supplements and
pharmaceuticals differ is because their chemistry differs.
The current risk assessment methodologies for chemicals regarding human
toxicity endpoints are often derived from those for preclinical studies of
pharmaceuticals. The methods for hazard assessment are largely the same for
industrial chemicals, pesticides, and drug candidates. But this approach may not
necessarily be appropriate for the risk assessment of herbal medicines now
available as dietary supplements. Understanding and using the information we
know about the action of phytochemicals present in herbal medicines, and the
chemistry associated with their toxicity, is being under-utilized in the production
of herbal dietary supplements, and their safety review by regulators.
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For dietary supplement safety concerns unrelated to adulteration,
contamination, or other manufacturing and quality control procedures, but rather
those that are inherent to the botanical preparations themselves, it is important to
understand the toxic liabilities associated with phytochemicals present in botanical
preparations in particular. It is to be acknowledged that herbal medicines, in use,
are usually complex mixtures whose dynamic pharmacology is the result of a
biochemical matrix of molecules that act to carry secondary metabolites
throughout the body. The biological action of complex botanical mixtures is
thought to be the result of isolable single molecule principles. Their bioactivity,
including toxicity, is the result of chemical structures and chemical properties.
The scientific discipline and collected wisdom encompassing the study of the
chemistry, pharmacology, and toxicology of these secondary metabolites and their
use in complex preparations is known as pharmacognosy. The findings of the
science of pharmacognosy can and should b e applied to the evaluation of the
safety of botanical dietary supplements.
In many cases, the active forms of secondary metabolites that are the basis
of any rational phytotherapy are often prodrugs whose active form is generated
through metabolic bioactivation in vivo, usually through Phase I metabolism.
Thus, the active forms of molecules giving rise to favorable bioactivity, as well as
toxic bioreactivity, is often the results of fleeting metabolites that fall into two
broad categories: free radicals, and reactive electrophiles that are highly water
soluble, and made more so by the oxidation, reduction, and hydrolysis resulting
from Phase I biotransforming enzymes, cytochromes p450 (CYP enzymes). Due
to the presence of reactive metabolites, the functional macromolecular structure of
endogenous targets, like proteins and nucleic acids, can be altered in vivo. Their
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effects range from chemoprevention in some cases, generally for weaker
electrophiles with longer half lives, and mutagenesis and cell death in others,
particularly for those that form briefly and whose targets are indiscriminate [11].
The resultant reactive intermediates can bind covalently to DNA and proteins,
leading to organ toxicity and even carcinogenicity. In addition, some
phytochemicals are shown to form reactive intermediates capable of irreversibly
inhibiting various CYPs, which are critical to the metabolism and elimination of
xenobiotics from the body, including therapeutic drugs. Less frequently, herbal
compounds can also be converted to toxic or carcinogenic metabolites through
Phase II metabolism enzymes that carry out reactions like glucoronidation
sulfonation, acetylation, methylation, and glutathione conjugation.
The fleeting, reactive nature of these compounds pose considerable
analytical challenges in attempts to determine their properties. It is understood that
herbal medicines, often comprised of multiple active substances, undergo
complicated fates in vivo. These fates can often be difficult to study, to follow and
trace throughout the body, as intermediates responsible for biological reactivity
are often fleeting in nature, and can be metabolized rapidly. For this reason,
attempts to understand the absorption, distribution, and metabolism (ADME) and
toxicity may best be accomplished by leveraging analysis of the structures isolated
from phytochemicals, and evaluating their ability to form BRIs in vivo.
Screening natural product structures isolated from herbals used in dietary
supplements for their likelihood to form such metabolites is an important step in
identifying potential liabilities [15]. This screening can be conducted via a
structure-based approach, in comparison with structures from herbal medicines
that are known to be toxic, or converted in vivo to electrophilic mutagens and
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carcinogens, and renal- or hepato-toxins. The study of reactive metabolites was
pioneered in the 1940s through the work of James and Elizabeth Miller, who
studied the mechanisms of action and metabolism of the carcinogenic azo dye 4dimethylaminoazobenzene (DAB), formerly used as a food coloring [95]. Further
study of the mechanisms of action and metabolic fate of a large number of
carcinogens led to the identification of several chemical functional groups and
substructures (Structural Alerts, SA) that are used to screen for toxic liabilities for
pharmaceuticals, environmental toxins, and food additives to this day [16, 96].
Many functional groups in chemical structures are known to be associated with
the formation of reactive metabolites, very often catalyzed by the CYP enzymes.
It is important to keep in mind, however, not all compounds with such functional
groups are toxic, since formation of reactive intermediates is limited by the ability
of CYPs to activate them.
Through the consideration of the types of biologically active compounds
that may be present in the plant, it is possible to make educated estimates of the
potential hazard of any given botanical, and prioritize their level of concern to
safety. In their 2005 publication, Dietary Supplements: A Framework for
Evaluating Safety, the National Academies of Science encouraged the use of
chemical relatedness, or similarities to known toxic chemical compounds when
considering the safety of botanical dietary supplements and their chemical
components [97]. In the absence of information about the activity of the ingredient
in question in humans, animals, or in vitro experiments, it is scientifically
acceptable and appropriate to use information about safety concerns of related
substances to inform a decision about the associated risk of the dietary supplement
ingredients and their constitutive phytochemistry.
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While most botanical dietary supplements can be considered safe, we know
the formation of reactive metabolites from compounds like saffrole (Sassafras oil),
aristolochic acid (Aristolochiaceae family, especially genus Aristolochia and
Assarum), methysticin (Kava Kava, Piper methysticum), and others have been
reported [92]. Their toxicity arises primarily from the presence of six biological
reactive intermediates, ranging in electrophilicity, from highly reactive and
positively charged, to more stable, neutral electrophiles: carbocations, nitrenium
ions, epoxides, quinones, quinone methides, and simple Michael acceptors (MAs).
Other structural alert groups exist within natural products, including acetylenes,
benzodioxoles, and terminal alkenes, among others (see Fig. 56). Of the 57 known
structural alerts associated with mutagenicity and genotoxic carcinogenicity, 16
regularly occur within botanical natural products [11, 98].
Awareness of the presence of these compounds can be used in early product
development, just as it is in early drug discovery, to evaluate the possibility of a
given compounds becoming a metabolic liability. The need to assess the ability of
a chemical to act as a mutagen or genotoxic carcinogen is one of the primary
requirements in regulatory toxicology, as is assessing the ability for a compound
to induce liver injury by inhibition of CYP enzymes [17, 21, 22, 24, 25].
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Fig. 59: Common Chemical Structural Alert Groups from
Natural Products
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Leveraging Accumulated Knowledge and Existent Strategies
Structural alerts (SAs) for toxicities like mutagenicity and carcinogenicity,
and CYP-related metabolism have been identified and codified into software
programs by using existing knowledge, expert human judgment, bioassay data,
and other modeling approaches [99]. These computer programs can assist in
predicting the potential propensity for a chemical, or libraries of chemicals, to
cause particular effects. A wide range of approaches and algorithms are
incorporated into metabolism prediction software, with some using the structural
features and physiochemical properties of test substrate compounds to predict the
most likely metabolic sites. Some also incorporate docking studies and molecular
dynamics simulation studies to assess P450-related pharmacological processes
[100]. Apart from predicting only the possibility of particular sites of metabolism
resulting from the biotransformation of a molecule, some software programs are
designed to calculate the probability of a compound to be metabolized at a
particular site, as well as other physiochemical parameters. Several proprietary,
but few public, in silico methods are available for assessing ADMET properties.
Whatever method or algorithm is used, in silico toxicology, or the
computational assessment of toxic liabilities, can allow researchers to evaluate a
large number of chemicals, with consideration for a variety of endpoints, and
ranges of exposure conditions considered simultaneously. Other benefits include
a substantial reduction, replacement, and refinement in the need for biological and
particularly animal toxicological testing in establishing the safety of chemical
substances. In addition, because bioactive and bioreactive intermediates formed
from phytochemicals are often fleeting intermediates produced in vivo, in silico
work has the added advantage of exploring these compounds in simulated studies.
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The strategy can be cost and time effective, and provides information that can
guide appropriate further testing and the conscientious use of resources.
These programs are used by regulators throughout the FDA, the EPA, by
industry and academic researchers alike to evaluate a wide variety of chemical
substances [101-103]. For instance, regulators at the US Food and Drug
Administration’s Office of Food Additive Safety (OFAS), who administer the
program that evaluates the safety information and industry submissions for
various categories of food substances, including food additives, employ structure
activity relationships (SAR) studies to evaluate the risk posed by new chemicals in
these submissions [16]. It has been pointed out elsewhere that the framework
wording and most of the scientific standards presented in the NDI draft guidance
for dietary supplements are borrowed heavily from the food additive review
process, so much so that the two “seem to be indistinguishable” [77, 104]. While
the testing frame work and scientific standards required for NDIs may be new to
the dietary supplement industry, regulators and manufacturers have already
encountered the challenges presented by these provisions to some extent within
the framework of food additive regulation, and developed working solutions to
these challenges. Computational screening for structural alerts generates threshold
of concern that then guides appropriate toxicological testing. A similar strategy
can and should be applied to the evaluation of dietary supplements, especially
considering that dietary supplements are to be regulated less stringently than food
additives, under DSHEA.
It is important to keep in mind that models are guides, not hard forecasts.
While a great deal of computational work, with a vast amount of expert
knowledge that allows for a broad scope evaluation of toxic liabilities associated
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with structures, it must be kept in mind that all models, even animal and cell
culture models, are approximations. In silico predictions are most often conducted
alongside other testing strategies, and these data constitute an integrated testing
strategy. Assessing the relative value of information derived from computational
toxicology can and should be weighed alongside other, different pieces of
available information that has been gathered when making an overall risk
assessment, and when considering what other information may be needed to
conduct a robust assessment.

Conclusion
The consumption of any botanical ingredient carries with it a certain degree
of inherent risk to at least some segments of the human population, even for those
plants used as foods or with a history of use for medicinal purposes.
In the absence of comprehensive human clinical trials that establish safety,
scientific evidence for risk can be obtained by considering whether the plant
constituents are compounds with established toxicity or closely related in structure
to compounds with established toxicity [32].
Electrophilic structural alert groups commonly associated with natural
product toxicity can be used to flag and identify potential natural product
liabilities. Because neither regulatory bodies nor dietary supplement
manufacturers have resources or time to conduct extensive toxicological testing,
we can use structural features of natural product compounds to help us focus on
areas of potential concern and prioritize efforts and resources. Computational
capacity can be leveraged to flag and compile this data, and alert us to potential
concerns. The basis of this work, however, is the isolation of chemical compounds
present in laboratories of pharmacognosy. Their work plays a vital role in the
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evaluation of potential toxicities associated with botanicals developed into dietary
supplements by providing chemical structures needed for this type of risk
assessment. Moreover, this data is required for new dietary ingredient (NDI)
submission, and should be fully utilized when considering a justification for a
reasonable expectation of safety. This helps both manufacturers and regulators
leverage existing data necessary for NDI submissions to appropriately evaluate
generalized potential risk profiles of botanical extract’s constitutive chemistry,
and prioritize needs for future toxicological testing.
DSHEA set out dietary supplements as a different level of premarket safety
concern from pharmaceuticals or food additives, because the chemical levels of
concern are different. Understanding and using the information we know about the
action of phytochemicals present in herbal medicines, and the chemistry
associated with their toxicity, is being under-utilized in the production of herbal
dietary supplements, and their safety review by regulators. Neither manufacturers
nor regulators have the resources available to do extensive pre-clinical testing of
individual new dietary ingredients, which include extensive animal testing, and to
review all the data that would be generated therefrom. The scientific
understanding of the phytochemistry and resultant pharmacology of natural
products should be better integrated in to the preliminary pre-market screening
required by the NDI submission process, as it has been by other sectors of food
and drugs, for which pre-market safety standards are more stringent. This
information can and should be used to direct and guide the appropriate biological
safety testing needed for herbal dietary supplements. Regulators and producers of
pharmaceuticals, pesticides, and food additives have previously used structural
alerts to help classify the safety or potential liability associated with compounds.
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Such a strategy can and should be applied to dietary supplements, to assess the
safety of their products, and to help prioritize their testing efforts.
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In silico ADME/TOX Evaluation of Compounds
Isolated from Iresine celosia and Related
Metabolites
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Introduction
The aim of this work was to evaluate the safety of isolated phytochemicals
from the Iresine celosia Odyliresin™ formulation using in silico drug metabolism
and toxicology simulation studies, to predict possible metabolites generated in
vivo, and their possible toxicological endpoints using ADMET predictor
proprietary software. Compounds isolated from Iresine celosia botanical extract
were screened using Simulations Plus ADMET Predictor proprietary software, to
develop recommended maximum-recommended therapeutic oral dose and
estimate overall toxic risk profiles of the compounds, including mutagenesis,
chromosomal aberrations, reproductive toxicity, and human liver adverse effects.
Previously, the extracts have been standardized, and the presence of guanidine
alkaloids that may represent the health-relevant principle of the extract, as
quantified. This work outlines the findings of screening these compounds for
ADME/Tox using proprietary systems pharmacology software. In addition, to
evaluate the formulation’s risk for potential herb-drug interactions, the ability of
these compounds to inhibit CYP450 enzymes was also evaluated. Because many
phytochemicals act as prodrugs, the generation of potentially bioactive or
bioreactive (toxic) metabolites through Phase I biotransformation was also
evaluated, and compared with botanical secondary metabolites known to cause
toxicity. In silico screening of individual compounds isolated from the
formulation suggest very little CYP inhibition a low level of safety concern
overall for the compounds evaluated. Overall, these data support a reasonable
expectation of safety when using this preparation as directed.
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Methods
Phytochemicals isolated from Iresine celosia and their CYP450-produced
biological metabolites were screened for their potential toxicity using the ADMET
predictor proprietary software, a modeling tool from Simulations Plus. The
ADMET Predictor Metabolism Module was used to determine whether
compounds screened would be substrates for the nine most common CYP
isoforms included in the model (2A6, 2B6, 2C8, 2E1, 1A2, 2C9, 2C19, 2D6 and
3A4), whether an atom within a molecule could be a metabolic site, and what the
predicted metabolite species could be. Metabolic site prediction models were
trained on an extensively curated and updated version of the Accelrys Metabolite
database along with published datasets of sites of metabolism and general review
articles. The data is curated and updated to reflect more recent publications, and
false positives removed when further literature investigations revealed a particular
reaction in question to be mediated by a different CYP or through a non-CYPenzyme. Published literature has also gone on to validate sites of metabolism
predicted by the model which were then experimentally verified, which suggests
an added degree of confidence in the metabolism prediction models.
The ADMET Predictor Toxicity Module is used to predict toxicity relative
to food products, pharmaceuticals, and environmental chemicals such as
pesticides. The toxicity module offers information on a variety of end points,
including estrogen and androgen receptor toxicity, chromosomal aberrations, a
qualitative filter of mutagenicity in five strains of Salmonella bacteria with and
without microsomal activation, human liver adverse effects, reproductive and
developmental toxicity, maximum recommended therapeutic dose (MRTD),
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carcinogenicity in rats and mice as TD50, and acute lethal toxicity in rats as
LD50, among others.
Parent structures were input into ADMET Predictor using MedChem
Designer. Analysis was run on these compounds with default settings, including
running on pH 7.4 and pH 2. Output data containing toxicity, metabolism, and
other physiochemical test results was exported to Excel for further analysis. Parent
structures were then put into MedChem Designer, to generate metabolite
structures and ADMET Predictor properties of metabolites taken. This data was
also exported to Excel for further analysis.
Both models have been used extensively by a variety of companies within
the pharmaceutical and chemical industries, as well as with the U.S. Food and
Drug Administration with whom the company has recently developed
collaborative agreement to further develop in vitro-in vivo correlation models to
streamline regulatory review. These models are also licensed for academic use at
steeply discounted rates, making them cost-effective for academic laboratories.
These models have been extensively curated, are updated regularly, and do
include some natural products in their data set. However, because natural products
are very difficult to track as they are metabolized throughout the body, the natural
product specific dataset that could inform metabolic site predictions and ADME
toxicity modules like the ones used are quite limited. Thus, one draw back to the
model that may exist is its training on pharmaceutical and environmental pesticide
compounds, for which there is a greater wealth of metabolic and toxicity data. In
addition, the model is unable to predict the formation of metabolites with short
half-lives, such as the formation of epoxides. While it can make predictions about
a compound’s ability to be metabolized by UGT-enzymes, it is primarily focused
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on the prediction of metabolites formed through the nine CYP-isoforms listed
above. Should a compound be metabolized by one of these enzymes, then undergo
a Phase I reaction like sulfonation prior to being further metabolized by one of the
CYP-enzymes included in the model, the model will be unable to make this
logical leap. Thus, study and awareness of examples of known natural product
metabolism were studied and also applied when evaluating results from both the
Metabolism and Toxicity modules.
Internal cross-validation of the model was conducted using a set of botanical
natural product structures known to inhibit CYP450 enzyme function, or to form
biologically reactive intermediates, derived primarily from the Botanical Safety
Handbook and other resources [12-14, 92].

Results
Enzymes primarily responsible for the metabolism of these GA compounds
are CYP219, 2C19, and 2E1. Compound 1 and Compound 3 can be expected to be
a substrate to CYP2C19 and 2E1. Compound 2 can be expected to be a substrate
to CYP2C19 but not to 2E1. Compound 1 is also likely to be metabolized by
CYP2D6. Compound 1 and 3 may be further metabolized through glucoronidation
via the UGT2B7 enzyme.
Compound 1 and 3 may be contraindicated with use alongside protein pump
inhibitors, as 2C19 is responsible for clearing this class of drugs. Because of
further glucoronidation via UGT2B7, these compounds may be contraindicated
with use in alcoholics and cancer patients. However, compounds 1 and 3 show
very low likelihood of acting as mutagens. They may cause adverse liver events,
but their maximum recommended therapeutic dose is high (above 3.16 mg/kg/day
for a 60 kg-body weight/day), indicating less potential for overall toxicity.
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For Compound 2, the maximum recommended therapeutic dose is lower
(below 3.16 mg/kg/day for a 60 kg-body weight/day). On further inspection,
however, when LD50 and TD50 values for rats and mice are examined, it is found
that the compound in its current formulation is present in concentration well
below the concentrations required to cause lethality and toxicity in 50% of the
respective populations.
Overall, these compounds each present an overall ADMET risk of 3/24,
indicating that they are relatively low in risk as compared with the World Drug
Index training set.
Outlines of findings for the guanidine alkaloid compounds are discussed
below.
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Overall Simulation Summary for Compound 1:
Compound 1 can be expected to be a substrate to CYPC19 and 2E1.
CYP2C19 is important in the clearance of several classes of exceptionally widely
used drugs, such as the proton pump inhibitors (PPIs) like clopidogrel, phenytoin
and S-mephenytoin, as well as barbiturates, benzodiazepines, SSRIs, and the
antimalarial proguanil. Possible contraindication with use alongside PPI (protein
pump inhibitors). This compound may be a CYP2E1 substrate (60% likelihood).
Very few drugs are cleared by 2E1, although it generates reactive oxygen species
without substrate present, and are thus implicated in liver malfunction in
alcoholics and cancer patients because of these reactive oxygen species. It is also
likely that this compound is further metabolized through glucoronidation via the
UGT2B7 enzyme. This enzyme is responsible for conjugation of bile acids,
catechol estrogens, morphine and naproxen, hydroxymidazolam, gemfibrozil,
AZT and many other drugs. Midazolam is also a substrate, and structurally similar
to this compound, with both sharing an imidazo- ring. Possible contraindication
with use in alcoholics, and cancer patients may be advised. Compound 1 does not
appear to pose a liability to overall CYP-function (CYP_RISK: 0).
Maximum recommended therapeutic oral dose (TOX_MRTD), based on mg
dosage/60kg-body weight/day, is above 3.16 mg/kg/day, indicating less potential
for overall toxicity. LD50 for lethal acute rat (TOX_RAT) in mg/kg oral dose that
would be lethal to 50% of rats was 768.94 mg/kg/day, requiring a 46.14 gram oral
dose for a 60kg-body weight/day. TD50 or oral dose required to induce tumors in
50% of rats after exposure over a standard lifetime (TOX_BRM_Rat), measured
in mg/kg/day oral dose, is 1.95 mg/kg/day. This would require a human equivalent
oral dose of 117 mg/day of the pure compound. In mice (TOX_BRM_Mouse), the
number is 75.25 mg/kg/day, equating to a 4.52 gram oral dose each day of the
single compound. TOX_Code Xr indicates that this compound may present a risk
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in terms of carcinogenicity in chronic rat studies, because TOX_BRM_Rat is
below 4 mg/kg/day oral dose. For a 60 kg body weight, that would amount to 240
mg/kg/day of the pure compound. With MRTD above 3.6 mg/kg/day, a LD50
calling for 46 gram/day oral dose, and a TD50 oral dose of pure compound at 117
mg/kg/day, the compound in its current formulation is so dilute as to be presumed
to be safe because it is present in an average daily dose in concentrations well
below the concentrations above.
With an overall mutagenicity score representing the results of virtual Ames
testing (TOX_MUT_Risk) of 1, on a score of 0-6 (with or without microsomal
activation), this compound is not likely to present a serious mutagenic risk. Out of
the ten virtual Ames tests conducted, this compound flagged one: an elevated risk
for a metabolite of the pure compound likely to cause mutagenesis in TA1535
strain of Salmonella typhimurium (TOX_MUT_m1535). Other qualitative risk
estimations for toxic liabilities may also include elevated risk for reproductive
toxin (TOX_REPR) at 72%, elevated risk for chromosomal aberration
(TOX_CABR) at 79%.
Human liver adverse effect as the likelihood of causing elevation in the
levels of a variety of liver enzymes, including elevated alkaline phosphatase
enzyme (TOX_AlkPhos) at 98%, elevated GGT enzyme (TOX_GGT) at 86%,
elevated LDH enzyme (TOX_LDH), elevated SGOT (TOX_SGOT) at 99%, and
elevated SGPT enzyme at 74%. Thus, extremely concentrated doses of this
compound may cause cardiac toxicity, chromosomal aberration, and reproductive
toxicity. Elevation at higher doses may result in increased levels of alkaline
phosphatase (98%), GGT (86%), LDH, SGOT (99%), and SGPT (74%) liver
enzymes. The binary value, yes/no, TOX_Code HP indicates that a combination
of liver enzymes levels would rise as a result of this compound, and that this
compound could result in hepatotoxicity. Further indication of liver damage or
disease, by the presence of higher levels of enzyme, the binary yes/no value,
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TOX_Code SG indicates increased levels in serum glutamic pyruvic transaminase
(SGPT), now known as alanine aminotransferase (ALT) may be elevated in the
presence of compound 1. Thus, this compound may cause increased levels of
enzymes involved with hepatotoxicity.
The model does not indicate that the compound would be toxic to the
androgen receptor or estrogen receptor in rats (TOX_AR_Filter and
TOX_AR_Filter).
With an overall ADMET_RISK composite score for all of these models, on
a scale of 0-24, this compound scored 3.

BRIs present in Compound 1:
Through CYP2E6, the oxidation of the secondary alcohol to a ketone, a Simple
Michael acceptor product is formed (metabolite 4, M4). This intermediate may be
a possible mutagen (TOX_Code Mut), TOX_MUT_Risk 2 (out of 0-6).

ADMET results:
CYP2C19 Substrate: Yes
CLint: 0.034
Intrinsic clearance constants for predicted sites of CYP2C19 mediated metabolism
expressed in uL/min/mg microsomal protein.

CYP2E1 Substrate: Yes (60%)
MET_UGT2B7: Yes, 97%.
Qualitative model of a glucoronidation by the UDP glucuronosyltransferase 2B7
enzyme. Responsible for conjugation of bile acids, catechol estrogens, morphine
and naproxen, hydroxymidazolam, gemfibrozil, AZT and many other drugs.
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Midrazolam is also a substrate, and structurally similar to this compound, with
both sharing an imidazo- ring.
Results: Further metabolism of this molecule via glucoronidation via the UGT2B7
enzyme is predicted.

CYP_RISK: 0
ADMET Code for metabolic liability - a computational filter developed by using a
refined subset of the WDI.

TOX_MRTD: Above 3.16 (65%)
A qualitative assessment of the maximum recommended therapeutic dose
administered as an oral dose in mg/kg/day.

TOX_MUT_Risk: 1
Represents the results of virtual Ames testing. Predicts overall mutagenicity by
counting the number of “Positive” mutagenicity predictions. On a score of 0-6
(with or without microsomal activation).
Result: We would not expect compound 1 to act as a mutagen.

TOX_MUT_Code: m4
Summarizes output of TOX_MUT_* models from the program. Accounts for the
compound’s metabolites.
Results: Metabolite 4 (m4) may be a possible mutagen (TOX_Code Mut), with a
TOX_MUT_Risk of 2 out of a 0-6 scale.

TOX_MUT_1535: Negative
Qualitative assessment of mutagenicity of the pure compound in TA1535 strain
of S. typhinmurium.

TOX_MUT_m1535: Positive (50%)
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Qualitative assessment of mutagenicity of the compound and its microsomal rat
liver metabolites in TA1535 strain of S. Typhinmurium.

TOX_Risk: 3
Score from 0-7, indicates the number of toxicity problems a compound might
have. An overall toxic liability score, derived from World Drug Index (this
includes natural product structures). Score exceeds 2 for ~10% focused WDI.
Results: This compound may present a low-moderate toxicological risk as a single
chemical entity. Dosing, formulation, and carrier vehicle chemistry should be
considered.

TOX_Code: Xr, HP, SG
Results:
Xr: This compound may present a risk in terms of carcinogenicity in chronic rat
studies.
HP: this compound may present a risk as a hepatotoxin.
SG: serum glutamic pyruvic transaminase (SGPT), now known as alanine
aminotransferase (ALT) test. Measured to see if the liver is damaged or diseased,
by presence of higher ALT levels. This compound may cause elevated levels of
ALT.

TOX_Rat: 768.94 mg/kg/day oral dose LD50
TOX_BRM_RAT: 1.95 mg/kg/day oral dose TD50
Predicts the TD50 value of a particular compound in units of mg/kg/day. The
TD50 is the dose of a substance administered orally to rats over the course of their
lifetimes that results in the appearance of tumors in 50 percent of their population.

TOX_BRM_MOUSE: 75.252 mg/kg/day oral dose TD50
Similar TD50 value for mouse model.
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TOX_CABR: Toxic (79%)
Qualitative estimation of triggering the mutagenic chromosomal aberrations.

TOX_REPR: Toxic (72%)
Qualitative estimation of reproductive / developmental toxicity.

TOX_AlkPhos: Elevated (98%)
Human liver adverse effect as the likelihood of causing elevation in the levels of
Alkaline Phosphatase enzyme.

TOX_GGT: Elevated
Human liver adverse effect as the likelihood of causing elevation in the levels of
GGT enzyme.

TOX_SGOT: Elevated (99%)
Human liver adverse effect as the likelihood of causing elevation in the levels of
SGOT enzyme.

TOX_SGPT: Elevated (74%)
Human liver adverse effect as the likelihood of causing elevation in the levels of
SGPT enzyme.

TOX_AR_Filter: Non-toxic to AR
Qualitative assessment of the androgen receptor toxicity in rats.

TOX_ER_Filter: Non-toxic to ER
Qualitative assessment of the estrogen receptor toxicity in rats.

Overall ADMET_Risk: 3
On a scale of 0-24. Summarizes all other ADMET Risk/Code models - a
computational filter developed by Simulations Plus Inc. using a refined subset of
the WDI.
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Overall Simulation Summary for Compound 2:
Compound 2 can be expected to be a substrate to CYPC19 but not to 2E1.
CYP2C19 is important in the clearance of several classes of exceptionally widely
used drugs, such as the proton pump inhibitors (PPIs) like clopidogrel, phenytoin
and S-mephenytoin, as well as barbiturates, benzodiazapenes, SSRIs, and the
antimalarial proguanil. Possible contraindication with use alongside PPI (protein
pump inhibitors). Compound 2 does not appear to pose a liability to overall CYPfunction (CYP_RISK: 0).
Maximum recommended therapeutic oral dose (TOX_MRTD), based on mg
dosage/60kg-body weight/day, is below 3.16 mg/kg/day, indicating some potential
for overall toxicity. On further inspection, however, LD50 and TD50 values are
still quite high. LD50 for lethal acute rat (TOX_RAT) in mg/kg oral dose that
would be lethal to 50% of rats was 721.84 mg/kg/day, requiring a 43.31 gram oral
dose for a 60kg-body weight/day. The TD50 or oral dose required to induce
tumors in 50% of rats after exposure over a standard lifetime (TOX_BRM_Rat),
measured in mg/kg/day oral dose, is 3.86 mg/kg/day. This would require a human
equivalent oral dose of 231.6 mg/day of the pure compound. In mice
(TOX_BRM_Mouse), the number is 91.36 mg/kg/day, equating to a 5.48 gram
oral dose each day of the single compound. TOX_Code Xr indicates that this
compound may present a risk in terms of carcinogenicity in chronic rat studies,
because TOX_BRM_Rat is below 4 mg/kg/day oral dose. For a 60 kg body
weight, that would amount to 240 mg/kg/day of the pure compound. The
compound in its current formulation is so dilute as to be presumed to be safe
because it is present in an average daily dose in concentrations well below
concentrations cited above.
With an overall mutagenicity score representing the results of virtual Ames
testing (TOX_MUT_Risk) of 1, on a score of 0-6 (with or without microsomal
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activation), this compound is not likely to present a serious mutagenic risk. Out of
the ten virtual Ames tests conducted, this compound flagged one: an elevated risk
for a metabolite of the pure compound likely to cause mutagenesis in TA1535
strain of Salmonella typhimurium (TOX_MUT_m1535). Other qualitative risk
estimations for toxic liabilities may also elevated risk for chromosomal aberration
(TOX_CABR) at 71%, but not a risk as a reproductive toxin (TOX_REPR) at
80%.
Human liver adverse effect as the likelihood of causing elevation in the
levels of a variety of liver enzymes, including elevated alkaline phosphatase
enzyme (TOX_AlkPhos) at 98%, elevated GGT enzyme (TOX_GGT) at 86%,
elevated LDH enzyme (TOX_LDH), elevated SGOT (TOX_SGOT) at 90%, and
elevated SGPT enzyme at 74%. Thus, extremely concentrated doses of this
compound may cause cardiac toxicity, chromosomal aberration, and reproductive
toxicity. Elevation at higher doses may result in increased levels of alkaline
phosphatase (98%), GGT (86%), LDH, SGOT (99%), and SGPT (74%) liver
enzymes. The binary value, yes/no, TOX_Code HP indicates that a combination
of liver enzymes levels would rise as a result of this compound, and that this
compound could result in hepatotoxicity. Further indication of liver damage or
disease, by the presence of higher levels of enzyme, the binary yes/no value,
TOX_Code SG indicates increased levels in serum glutamic pyruvic transaminase
(SGPT), now known as alanine aminotransferase (ALT) may be elevated in the
presence of compound 2. Thus, this compound may cause increased levels of
enzymes involved with hepatotoxicity.
The model does not indicate that the compound would be toxic to the
androgen receptor or estrogen receptor in rats (TOX_AR_Filter and
TOX_AR_Filter).
With an overall ADMET_RISK composite score for all of these models, on
a scale of 0-24, this compound scored 3.
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BRIs present in Compound 2:
Through CYP2C19, a potential simple Michael Acceptor is formed (metabolite 4,
M4). This intermediate may be a possible mutagen (TOX_Code Mut),
TOX_MUT_Risk of 3 (out of 0-6).

ADMET results:
CYP2C19 Substrate: Yes
CLint: 0.0145
Intrinsic clearance constants for predicted sites of CYP2C19 mediated metabolism
expressed in uL/min/mg microsomal protein.

CYP2E1 Substrate: Non-substrate
MET_UGT2B7: Yes, 97%.
Qualitative model of a glucoronidation by the UDP glucuronosyltransferase 2B7
enzyme. Responsible for conjugation of bile acids, catechol estrogens, morphine
and naproxen, hydroxymidazolam, gemfibrozil, AZT and many other drugs.
Midrazolam is also a substrate, and structurally similar to this compound, with
both sharing an imidazo- ring.
Results: Further metabolism of this molecule via glucoronidation via the UGT2B7
enzyme is predicted.

CYP_RISK: 0
ADMET Code for metabolic liability - a computational filter developed by using a
refined subset of the WDI.

TOX_MRTD: Below 3.16 (56%)
A qualitative assessment of the maximum recommended therapeutic dose
administered as an oral dose in mg/kg/day.
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TOX_MUT_Risk: 1
Represents the results of 10 virtual Ames tests. Predicts overall mutagenicity by
counting the number of “Positive” mutagenicity predictions. On a score of 0-6
(with or without microsomal activation).
Result: We would not expect compound 2 to act as a mutagen.

TOX_MUT_Code: m4
Summarizes output of TOX_MUT_* models from the program. Accounts for the
compound’s metabolites.
Results: Metabolite 4 (m4) may be a possible mutagen (TOX_Code Mut), with a
TOX_MUT_Risk of 2 out of a 0-6 scale.

TOX_MUT_1535: Negative
Qualitative assessment of mutagenicity of the pure compound in TA1535 strain
of S. Typhinmurium.

TOX_MUT_m1535: Positive (58%)
Qualitative assessment of mutagenicity of the compound and its microsomal rat
liver metabolites in TA1535 strain of S. Typhinmurium.

TOX_Risk: 3
Score from 0-7, indicates the number of toxicity problems a compound might
have. An overall toxic liability score, derived from World Drug Index (this
includes natural product structures). Score exceeds 2 for ~10% focused WDI.
Results: This compound may present a low-moderate toxicological risk as a single
chemical entity. Dosing, formulation, and carrier vehicle chemistry should be
considered.

108

TOX_Code: Xr, HP, SG
Results:
Xr: This compound may present a risk in terms of carcinogenicity in chronic rat
studies.
HP: this compound may present a risk as a hepatotoxin.
SG: serum glutamic pyruvic transaminase (SGPT), now known as alanine
aminotransferase (ALT) test. Measured to see if the liver is damaged or diseased,
by presence of higher ALT levels. This compound may cause elevated levels of
ALT.

TOX_Rat: 721.84 mg/kg/day oral dose LD50
TOX_BRM_RAT: 3.86 mg/kg/day oral dose TD50
Predicts the TD50 value of a particular compound in units of mg/kg/day. The
TD50 is the dose of a substance administered orally to rats over the course of their
lifetimes that results in the appearance of tumors in 50 percent of their population.

TOX_BRM_MOUSE: 91.36 mg/kg/day oral dose TD50
Similar TD50 value for mouse model.

TOX_CABR: Toxic (71%)
Qualitative estimation of triggering the mutagenic chromosomal aberrations.

TOX_REPR: Non-toxic
Qualitative estimation of reproductive / developmental toxicity.

TOX_AlkPhos: Elevated (98%)
Human liver adverse effect as the likelihood of causing elevation in the levels of
Alkaline Phosphatase enzyme.

TOX_GGT: Elevated (70%)
Human liver adverse effect as the likelihood of causing elevation in the levels of
GGT enzyme.
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TOX_SGOT: Elevated (90%)
Human liver adverse effect as the likelihood of causing elevation in the levels of
SGOT enzyme.

TOX_SGPT: Elevated (74%)
Human liver adverse effect as the likelihood of causing elevation in the levels of
SGPT enzyme.

TOX_AR_Filter: Non-toxic to AR
Qualitative assessment of the androgen receptor toxicity in rats.

TOX_ER_Filter: Non-toxic to ER
Qualitative assessment of the estrogen receptor toxicity in rats.

Overall ADMET_Risk: 3
On a scale of 0-24. Summarizes all other ADMET Risk/Code models - a
computational filter developed by Simulations Plus Inc. using a refined subset of
the WDI.
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Overall Simulation Summary for Compound 3:
Compound 3 can be expected to be a substrate to CYPC19 and 2E1.
CYP2C19 is important in the clearance of several classes of exceptionally widely
used drugs, such as the proton pump inhibitors (PPIs) like clopidogrel, phenytoin
and S-mephenytoin, as well as barbiturates, benzodiazapenes, SSRIs, and the
antimalarial proguanil. Possible contraindication with use of this compound
alongside PPI (protein pump inhibitors). This compound may be a CYP2E1
substrate (60% likelihood). Very few drugs cleared by 2E1, although it generates
reactive oxygen species without substrate present, and are thus implicated in liver
malfunction in alcoholics and cancer patients because of these reactive oxygen
species. It is also likely that this compound is further metabolized through
glucoronidation via the UGT2B7 enzyme. This enzyme is responsible for
conjugation of bile acids, catechol estrogens, morphine and naproxen,
hydroxymidazolam, gemfibrozil, AZT and many other drugs. Midrazolam is also
a substrate, and structurally similar to this compound, with both sharing an
imidazo- ring. Possible contraindication with use in alcoholics, and cancer patients
may be advised. Compound 3 does not appear to pose a liability to overall CYPfunction (CYP_RISK: 0).
Maximum recommended therapeutic oral dose (TOX_MRTD), based on mg
dosage/60kg-body weight/day, is above 3.16 mg/kg/day, indicating less potential
for overall toxicity. LD50 for lethal acute rat (TOX_RAT) in mg/kg oral dose that
would be lethal to 50% of rats was 985.77 mg/kg/day, requiring a 59.15 gram oral
dose for a 60kg-body weight/day. The TD50 or oral dose required to induce
tumors in 50% of rats after exposure over a standard lifetime (TOX_BRM_Rat),
measured in mg/kg/day oral dose, is 15.23 mg/kg/day. This would require a
human equivalent oral dose of 913.8 mg/day of the pure compound. In mice
(TOX_BRM_Mouse), the number is 38.27 mg/kg/day, equating to a 2.30 gram
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oral dose each day of the single compound. The compound in its current
formulation is so dilute as to be presumed to be safe.
With an overall mutagenicity score representing the results of virtual Ames
testing (TOX_MUT_Risk) of 0, on a score of 0-6 (with or without microsomal
activation), this compound is not likely to present a serious mutagenic risk. No
risk for chromosomal aberration (TOX_CABR) at 94%, or as a reproductive toxin
(TOX_REPR) at 75% was found.
Human liver adverse effect as the likelihood of causing elevation in the
levels of a variety of liver enzymes, including elevated alkaline phosphatase
enzyme (TOX_AlkPhos) at 98%, elevated GGT enzyme (TOX_GGT) at 86%,
elevated LDH enzyme (TOX_LDH), elevated SGOT (TOX_SGOT) at 76%, and
elevated SGPT enzyme at 66%. Thus, extremely concentrated doses of this
compound may cause cardiac toxicity, chromosomal aberration, and reproductive
toxicity. Elevation at higher doses may result in increased levels of alkaline
phosphatase (98%), GGT (86%), LDH, SGOT (76%), and SGPT (66%) liver
enzymes. The binary value, yes/no, TOX_Code HP indicates that a combination
of liver enzymes levels would rise as a result of this compound, and that this
compound could result in hepatotoxicity. Further indication of liver damage or
disease, by the presence of higher levels of enzyme, the binary yes/no value,
TOX_Code SG indicates increased levels in serum glutamic pyruvic transaminase
(SGPT), now known as alanine aminotransferase (ALT) may be elevated in the
presence of compound 3. Thus, this compound may cause increased levels of
enzymes involved with hepatotoxicity.
The model does not indicate that the compound would be toxic to the
androgen receptor or estrogen receptor in rats (TOX_AR_Filter and
TOX_AR_Filter).
With an overall ADMET_RISK composite score for all of these models, on
a scale of 0-24, this compound scored 3.
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BRIs present in Compound 1:
None indicated.

ADMET results:
CYP2C19 Substrate: Yes
CLint: 12.9
Intrinsic clearance constants for predicted sites of CYP2C19 mediated metabolism
expressed in uL/min/mg microsomal protein.

CYP2D6 Substrate: Yes (98%)
CLint: 5.0
MET_2D6_Inh: Yes
CYP2E1 Substrate: Yes (58%)
MET_UGT1A6: Yes, 58%.
Qualitative model of a glucoronidation by the UDP glucuronosyltransferase 1A6
enzyme. Metabolizes small, planar, and phenolic chemicals.
Results: Further metabolism of this molecule via glucoronidation via the UGT1A6
enzyme is predicted.

CYP_RISK: 0
ADMET Code for metabolic liability - a computational filter developed by using a
refined subset of the WDI.

TOX_MRTD: Above 3.16 (56%)
A qualitative assessment of the maximum recommended therapeutic dose
administered as an oral dose in mg/kg/day.

TOX_MUT_Risk: 0
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Represents the results of 10 virtual Ames tests. Predicts overall mutagenicity by
counting the number of “Positive” mutagenicity predictions. On a score of 0-6
(with or without microsomal activation).
Result: We would not expect compound 3 to act as a mutagen.

TOX_Risk: 2
Score from 0-7, indicates the number of toxicity problems a compound might
have. An overall toxic liability score, derived from World Drug Index (this
includes natural product structures). Score exceeds 2 for ~10% focused WDI.
Results: This compound may present a low-moderate toxicological risk as a single
chemical entity. Dosing, formulation, and carrier vehicle chemistry should be
considered.

TOX_Code: HD, HP, SG
Results:
HD: This compound possesses hydrogen bond donors.
HP: this compound may present a risk as a hepatotoxin.
SG: serum glutamic pyruvic transaminase (SGPT), now known as alanine
aminotransferase (ALT) test. Measured to see if the liver is damaged or diseased,
by presence of higher ALT levels. This compound may cause elevated levels of
ALT.

TOX_Rat: 985.77 mg/kg/day oral dose LD50
TOX_BRM_RAT: 15.23 mg/kg/day oral dose TD50
Predicts the TD50 value of a particular compound in units of mg/kg/day. The
TD50 is the dose of a substance administered orally to rats over the course of their
lifetimes that results in the appearance of tumors in 50 percent of their population.

TOX_BRM_MOUSE: 38.27 mg/kg/day oral dose TD50
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Similar TD50 value for mouse model.

TOX_CABR: Toxic (71%)
Qualitative estimation of triggering the mutagenic chromosomal aberrations.

TOX_REPR: Non-toxic
Qualitative estimation of reproductive / developmental toxicity.

TOX_AlkPhos: Elevated (98%)
Human liver adverse effect as the likelihood of causing elevation in the levels of
Alkaline Phosphatase enzyme.

TOX_GGT: Elevated (70%)
Human liver adverse effect as the likelihood of causing elevation in the levels of
GGT enzyme.

TOX_SGOT: Elevated (90%)
Human liver adverse effect as the likelihood of causing elevation in the levels of
SGOT enzyme.

TOX_SGPT: Elevated (74%)
Human liver adverse effect as the likelihood of causing elevation in the levels of
SGPT enzyme.

TOX_AR_Filter: Non-toxic to AR
Qualitative assessment of the androgen receptor toxicity in rats.

TOX_ER_Filter: Non-toxic to ER
Qualitative assessment of the estrogen receptor toxicity in rats.

Overall ADMET_Risk: 3
On a scale of 0-24. Summarizes all other ADMET Risk/Code models - a
computational filter developed by Simulations Plus Inc. using a refined subset of
the WDI.
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Conclusions
Phytochemicals isolated from Iresine celosia and their CYP450-produced
biological metabolites were screened for their potential toxicity using the ADMET
predictor proprietary software, a modeling tool from Simulations Plus. The
software was also used to predict metabolites formed from chemical structures
within the body, to analyze whether these structures are likely to go on to cause
toxicity, and to determine the ability of these compounds to interfere with other
drug substances, by way of their ability to inhibit Cytochrome P450 (CYP) drug
metabolizing enzymes.
ADMET Predictor proved capable of predicting CYP sites of metabolism.
ADMET Predictor was found unable to handle Michael addition reactions
(including when these reactions were CYP mediated). ADMET Predictor unable
to handle epoxides or arene oxides, because of the extremely brief and fleeting
nature of these compounds, but it was correctly predict oxidation of phenyl ring at
para position, which is the result of an epoxide-forming reaction. Most O- and Ndealkylations were also correctly predicted from test studies. Overall, the program
accomplished what it sets out to do: to cover the most commonly observed
potential sites of oxidation.
Based on the information obtained from in silico screening of compounds
isolated from Iresine celosia formulation, a reasonable expectation of safety is
warranted when using this preparation as directed.
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Conclusion
Through a comprehensive phytochemical evaluation, phytochemical
compounds present within the Odyliresin™ formulation have been isolated, and
identified using a variety of chromatographic and spectroscopic techniques,
including HR-MS, NMR, HPLC-UV, FT-IR and CD spectroscopy. Unique
botanical marker compounds have been identified, which allows for authentication
of the identity of the botanical and standardization of the formulation extract.
Methods have been developed to isolate these compounds, and fingerprint profiles
generated to characterize the extract. These compounds are structurally rare within
the plant kingdom, and contain stereochemical complexity that derivatization and
crystallization methods have failed to resolve. At present, we are using electronic
circular dichroism (E-CD) and computer simulations to attempt to resolve the
three stereocenters, with a total of 8 possible overall conformations.
Biological activity of these compounds has been screened using in silico
docking experiments with the human androgen receptor (AR), prostate-cancer
relevant mutant types and wild type varieties. This preliminary information
supported further testing in vitro and the marker compounds did, in fact, prove
active on the 12.5 to 50 µM range. This data suggests that I. celosia may have
implications in promoting prostate health. Additional testing of the compound for
mechanism of action studies could be interesting. Based on comparable in silico
docking results as EGCG and aristolochic acid, known antiandrogens, it is
possible that these compounds may also work to competitively inhibit the binding
of testosterone to the AR. However, further testing through receptor based
competitive inhibition assays would be necessary.

118

These compounds were also screened for biological activity and reactivity,
based on the presence of natural product specific biologically reactive
intermediates. The compounds were further screened in silico using proprietary
computational toxicology software, Simulations Plus. Sites of metabolism and
CYP-inhibition were considered, as were mutagenicity, implications adverse liver
function, and general dosing, among other considerations. Guanidine alkaloid
compounds 1, 2, and even 3 are metabolized primarily by the CYP2C19, however,
CYP219, 2E1 and 2D6 may also play a role in their clearance from the body.
Phase II glucoronidation of these compounds is also likely, with UGT2B7 also
becoming involved. Predicted metabolites were also screened for their reactivity.
Further animal studies could be useful to confirm LD50 and TD50 values derived
from computational simulation, in either rat or mouse. However, it is likely that
the toxicity arising from the use of these individual compounds within
concentrated doses of the extract is quite low. Therefore, animal studies conducted
on a small scale and in one species may be sufficient to obtain the confirmatory
information needed. Overall, a generalized evaluation of the safety and risk profile
of the botanical’s individual compounds was obtained, from which can be
extrapolated a low level of risk when using this product as directed.
It is important to keep in mind that the formulation is not comprised solely of
active principles, but that the formulation is a plant extract containing a variety of
compounds, but health relevant and those that may be irrelevant. Similarly, the
cell testing assays we conduct and docking simulations are simplified models that
consider the individual structures themselves. Only by considering the totality of
this information can we approximate the possible biological activity of the
formulation in total. The study of complex botanical materials is its own
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discipline, and attempts to find isolable principles and standardize these extracts
currently represents the most useful strategy toward understanding their activity in
humans. The natural variety inherent in preparations, in growing conditions, in
species evolution from a chemocentric perspective, the complex matrix in which
what are thought to be active principles are delivered to the body is often
discounted, and can present challenges to the standardization of such preparations.
Based on HPLC standardization of the Odyliresin™ formulation of Iresine
celosia, it’s difficult to assess whether these compounds would be present in
enough quantity to affect a health outcome. However, synergistic effects of
compounds within the extract may play a role in its biological activity. Such
information could not be obtained from computational toxicology studies at this
time, and in such a case, the thoughtful conduct of animal studies may prove
helpful in further elucidating the formulation’s modes of action.
Chemistry is the key to understanding natural products, and considering
whether herbal medicines “work” and whether or not they are safe. At present, the
advances in chemistry have far outpaced the development of clinical
pharmacology and toxicology to understand the working of complex botanical
mixtures. Because definitive pharmacological and toxicological results are hard to
come by with respect to herbal medicines, some take this to mean that herbals
have no actual health effect, and therefore no basis in therapy from a scientific
perspective. Nevertheless, people continue to buy, ingest, and use herbal products.
Chemistry present in herbal products becomes part of the larger biochemical
milieu of items people ingest and substances to which people are exposed, which
also includes food, water, and alcohol, too. Because this complex milieu is
difficult to study, and at present only being tackled in the realm of systems

120

pharmacology; because chemistry is by far the most advanced scientific
expression of ethnopharmacology — it seems reasonable to leverage what we
know to be true about the chemistry and bioactivity/bioreactivity profile of these
compounds and use it to consider compounds for which information is lacking,
and distinguish thresholds of concern that may warrant further testing to ensure a
reasonable expectation of safety.
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Supporting Information Available
For Compound 1

Figure S1. 1H NMR spectrum of Compound (1) in (CD3)2S=O
Figure S2. 13C NMR spectrum of Compound (1) in (CD3)2S=O
Figure S3. COSY correlations of Compound (1) in (CD3)2S=O
Figure S4. COSY spectrum of Compound (1) in (CD3)2S=O
Figure S5: HSQC spectrum of Compound (1) in (CD3)2S=O
Figure S6: HMBC correlations (H -> C) for Compound (1) in (CD3)2S=O
Figure S7: HMBC spectrum (H -> C) of Compound (1),in (CD3)2S=O,
unexchanged
Figure S8: HMBC spectrum (H ->C) of Compound (1), proton exchanged with
D2 O
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Figure S9. NOESY correlations of Compound (1) in (CD3)2S=O
Fig. S10. NOESY spectrum of Compound (1) in (CD3)2S=O
Fig. S11. NOESY spectrum of (1) in (CD3)2S=O, with irradiated proton at 3.82
ppm
Fig. S12. NOESY spectrum of (1) in (CD3)2S=O, with irradiated proton at 3.46
ppm
Figure S13. 1H NMR spectrum of Compound (1) in (CD3)2S=O, unexchanged
Figure S14. 1H NMR spectrum of Compound (1) in (CD3)2S=O, exchanged with
D2 O

For Compound 2

Figure S1. 1H NMR spectrum of Compound (2) in (CD3)2S=O
Figure S2. 1H NMR spectrum of Compound (2) in (CD3OD)
Figure S3. COSY correlations of Compound (2) in (CD3)2S=O
Figure S4. COSY spectrum of Compound (2) in (CD3)2S=O
Figure S5. 13C NMR spectrum of Compound (2) in (CD3)2S=O
Figure S6: HSQC spectrum of Compound (2) in (CD3)2S=O
Figure S7: HMBC correlations (H -> C) of Compound (2) in (CD3)2S=O
Figure S8: HMBC spectrum (H -> C) of Compound (2) in (CD3)2S=O
Figure S9. 1H NMR spectrum of Compound (2) in (CD3)2S=O, unexchanged
Figure S10. 1H NMR spectrum of Compound (2) in (CD3)2S=O, exchanged with
D2 O
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Iresine celosia aerial material (2000 g)
Extracted with 30% ethanol, 16 L
9 L collected; dried to 1.2 mL
Extracted with n-Hexane

Aqueous layer

n-Hexane-soluble fraction (0.4 g)

Extracted with
EtoAC

EtOAc-soluble fraction (3 g viscous)

Aqueous layer

Extracted with
n-BuOH
n-BuOH-soluble fraction (8.93 g)

H2O-soluble fraction

Silica Gel CC
5.5 g
CHCl3 and MeOH

Fraction A
(0.85 g)

Fraction B-D
(0.84 g)

Sephadex LH-20
(0.8 g)
MeOH

Fraction E
(1.2 g)

Fraction F
(2.8 g)

Sephadex LH-20
(1g)
MeOH

24A
(0.37 g)

20 A-D
(0.56 g)

20E
(0.113 g)

20G
(0.038 g)

20F
(0.060 g)

24B
(0.3 g)

Semi-preparative
HPLC

Semi-preparative
HPLC
Compound 7, 8, 9, 11
(3.5, 13, 3.2, 3 mg)

Compound 4, 10
(0.7, 1.8 mg)

Compound 5, 6
(2.8, 2.8 mg)

Compound 1, 2, 3
(25, 5.7, 2.3 mg)

Figure 5: Isolation scheme for Iresine celosia
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Figure 6. 1H NMR spectrum of Compound (1) in (CD3)2S=O, unexchanged

Figure 7. 1H NMR spectrum (1) in (CD3)2S=O, exchanged with D2O
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Figure 8. COSY correlations of Compound (1) in (CD3)2S=O

Figure 9. COSY spectrum of Compound (1) in (CD3)2S=O
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Figure 10. 13C NMR spectrum of Compound (1) in (CD3)2S=O

Figure 11. HSQC spectrum of Compound (1) in (CD3)2S=O
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Figure 12. HMBC correlations (H -> C) for Compound (1) in (CD3)2S=O

Figure 13: HMBC spectrum (H -> C) for Compound (1), in (CD3)2S=O,
unexchanged
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Figure 14: HMBC spectrum (H ->C) for Compound (1), proton exchanged with
D2 O
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Figure 15. Key NOESY correlations of Compound (1) in (CD3)2S=O

Figure 16. NOESY spectrum of Compound (1) in (CD3)2S=O
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Figure 17. NOESY Spectrum of Compound (1) in (CD3)2S=O,
with irradiated proton at 3.82ppm

Figure 18. NOESY spectrum of Compound (1) in (CD3)2S=O,
with irradiated proton at 3.46 ppm
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Figure 19: IR Spectrum of Compound (1)

Figure 20: MS Spectrum for Compound (1)
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Table 5. Spectral Assignments for Compound (2)
Position

δ C (mult.)

δ H (mult., J in
Hz)

COSY

HMBC

1
2
3
4
5
6
3'
4'
1"
2"
3"
4"

18.17, 3H
138.45
117.42
41.87, 2H
25.86, 3H

1.73, s

H-4

3.95, dd (7.1)
1.79, s
5.18, t (7.1)
8.05, s

H-6, H-1
H-4
H-4

C-5, C-3, C-2
H-5, H-4, H-1
H-5, H-4, H-1
C-3, C-2, C-4’, C-4”
C-3, C-2, C-1
C-5, C-1

5”
6"

175.59
1H

2H
159.14
12.87, 3H
43.73, 1H
54.53, 1H
50.88, 2H

1.14, d (7.1)
2.56, m
4.11, m (10.1, 6.3)
3.72, dd (10.1)
3.36, dd (10.1, 6.3)
12.69, s
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H-2”
H-3”, H-1”
H-4”, H-2”
H-4”, H-3”
H-4”, H-3”

H-4, H-4”
C-5”, C-3”, C-2”
C-5”. C-3”, C-1”
C-5”, C-4”, C-1”
C-3”, C-2”
C-3”, C-2”
H-2”, H-1”

Figure 21. 1H NMR spectrum of Compound (2) in (CD3)2S=O, unexchanged

Figure 22. 1H NMR spectrum of Compound (2) in (CD3)2S=O, exchanged with
D2 O
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Figure 23. Key 1H -> 1H COSY correlations of Compound (2) in (CD3)2S=O

Figure 24. COSY spectrum of Compound (2) in (CD3)2S=O
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Figure 25. 13C NMR spectrum of Compound (2) in (CD3)2S=O

Figure 26: HSQC spectrum of Compound (2) in (CD3)2S=O
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Figure 27: HMBC correlations (H -> C) for Compound (2) in (CD3)2S=O

Figure 28: HMBC spectrum (H -> C) for Compound (2) in (CD3)2S=O

137

Figure 29: IR spectrum of Compound (2)

Figure 30: MS Spectrum for Compound (2)
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Table 6. Spectral Assignments for Compound (3),
Hydroxygalegine
Position

δ C (mult.)

2
5
6
7
8
10

156.34
45.5, 2H
119.52, 1H
140.28
60.53, 2H
20.97, 3H

δ H (mult., J in Hz) COSY

HMBC
H-5

4.09, d (7.1)
5.31, t (7.1)

H-10, H-6
H-10, H-5

4.12, s
1.81, s

H-6, H-5
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H-8, H-5. H-10
H-8, H-5. H-10
H-6, H-10
H-6, H-8

Figure 31. 1H spectrum of Compound (3) in CD3OD

Figure 32. 13C spectrum of Compound (3) in CD3OD
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Figure 33. COSY spectrum of Compound (3) in CD3OD

Figure 34. HMBC spectrum of Compound (3) in CD3OD
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Figure 35. HSQC spectrum of Compound (3) in CD3OD
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Table 7. Ligand Binding Affinities for Control Structures with
WT and Mutant Androgen Receptors
PBD ID#

Ligand

2YHD

testosterone

1I37

2Q7K
2YHD

dihydrotestosterone

1I37

2Q7K

2YHD

stigmasterol

1I37

2Q7K

2YHD

betasitosterol

1I37
2Q7K

2YHD

atraric acid

1I37

2Q7K

2YHD
1I37
2Q7K

EGCG

affinity
kcal/mol
-11.2
-8.9
-8.4
-11.2
-9.3
-8.3
-11.8
-10.2
-9.4
-9.4
-10.9
-9.5
-9.2
-11.3
-10.1
-9.9
-1.7
-1.5
-0.3
-1.6
-1.5
-0.3
-1.9
-1.4
-0.8
-2.3
-1.1
-0.5
-0.1
-2.8
-0.5
-1.2
-1.2
-6.1
-5.9
-5.8
-6.3
-5.9
-5.9
-6.8
-6.7
-6.2
-6.8
-6.8
-4.2
-4.1
-6.0
-6.0
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rmsd l.b.
0
1.472
1.214
0
1.148
1.477
0
0
1.529
1.145
0
1.110
1.273
0
1.150
1.180
0
2.781
1.577
0
2.782
2.838
0
2.795
0.890
0
2.796
2.777
0
1.228
0
2.881
2.792
0
1.547
2.259
0
2.232
1.983
0
0.665
1.905
0
0.014
0
0.005
0
0.030

Dist from best mode,
rmsd u.b.
0
6.158
6.579
0
6.536
2.715
0
0
2.897
6.123
0
6.095
2.573
0
6.093
2.544
0
7.429
3.298
0
7.433
7.497
0
8.079
2.486
0
7.498
7.364
0
2.848
0
7.442
7.508
0
1.859
5.216
0
3.037
5.014
0
1.158
5.012
0
1.443
0
1.443
0
1.443

Table 8. Ligand Binding Affinities for I. celosia Structures with
WT and Mutant Androgen Receptors
PBD
ID#
2YHD

Ligand

affinity kcal/mol

compound 1

-6.6
-6.5
-6.4
-6.8
-6.8
-6.6
-7.1
-7.0
-7.0
-6.8
-6.8
-6.6
-6.7
-6.7
-6.6
-7.1
-7.0
-7.0
-5.1
-5.0
-4.8
-5.3
-5.2
-4.9
-5.5
-5.4
-5.2
-7.3
-6.1
-6.0
-6.3
-5.7
-5.7
-6.7
-6.4
-6.1
-7.3
-7.2
-7.1
-7.2
-6.9
-6.9
-7.6
-7.6
-7.3
-8.5
-8.1
-8.1
-8.4
-8.4
-8.2
-9.0
-9.0
-8.7

1I37
2Q7K
2YHD

compound 2

1I37
2Q7K
2YHD

hydroxygalegine

1I37
2Q7K
2YHD

tlatancuayin

1I37
2Q7K
2YHD

drimane 2b

1I37
2Q7K
2YHD
1I37
2Q7K

drimane 3
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rmsd
l.b.
0
2.251
2.147
0
1.507
1.947
0
2.195
1.409
0
3.537
3.611
0
1.703
1.386
0
3.599
3.234
0
0.993
3.163
0
1.052
3.516
0
1.279
3.479
0
1.739
1.612
0
1.792
1.215
0
1.813
1.622
0
1.389
1.364
0
1.292
1.488
0
1.375
1.353
0
1.575
1.708
0
1.643
1.542
0
1.534
1.622

Dist from best mode,
rmsd u.b.
0
5.559
5.984
0
1.875
6.062
0
5.709
1.851
0
5.840
5.954
0
2.434
1.847
0
5.995
5.757
0
1.156
4.828
0
1.527
4.812
0
1.747
4.904
0
7.080
7.120
0
6.695
2.555
0
7.315
7.087
0
5.513
5.244
0
5.490
3.227
0
5.516
3.00
0
5.636
5.957
0
5.424
5.643
0
5.641
5.463

Table 9. Ligand Binding Affinities for Natural Product Structures
Associated with Prostate Health with WT and Mutant ARs
PBD ID#

Ligand

affinity kcal/mol

2YHD

apigenin

-8.6
-8.2
-8.1
-7.5
-7.4
-7.3
-9.1
-9.0
-8.8
-8.4
-7.8
-7.5
-8.0
-7.9
-6.5
-8.6
-8.6
-8.5
-8.7
-8.4
-8.4
-8.2
-8.0
-6.8
-9.1
-8.9
-8.9
-9.2
-9.1
-9.1
-9.3
-8.8
-8.3
-10.1
-9.6
-9.4
-7.7
-7.2
-5.7
-6.9
-5.3
-5.2
-7.2
-6.1
-5.7
-5.8
-5.7
-5.4
-2.9
-2.9
-2.8
-3.7
-3.7
-3.6

1I37
2Q7K
2YHD

baicalein

1I37
2Q7K
2YHD

emodin

1I37
2Q7K
2YHD

genistein

1I37
2Q7K
2YHD

icaritin

1I37
2Q7K
2YHD
1I37
2Q7K

xanthohumol
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rmsd
l.b.
0
2.102
2.037
0
0.124
1.995
0
0.032
2.091
0
2.522
2.540
0
2.337
1.723
0
0.019
1.878
0
1.348
1.192
0
1.473
1.116
0
1.501
1.150
0
1.148
1.137
0
1.469
1.546
0
1.183
1.272
0
1.365
2.073
0
2.004
1.503
0
1.457
2.025
0
1.420
1.925
0
2.038
12.33
0
1.717
1.040

Dist from best mode,
rmsd u.b.
0
3.740
6.748
0
1.076
6.568
0
1.074
3.658
0
6.121
6.505
0
6.491
3.319
0
1.074
3.391
0
5.535
1.347
0
5.560
3.221
0
5.572
3.306
0
6.884
6.806
0
6.965
7.143
0
6.882
6.819
0
1.720
7.059
0
7.105
2.078
0
1.930
7.057
0
3.829
7.397
0
3.288
14.592
0
4.113
1.580

Butanol Extract

Figure 36: In vitro prostate cancer cell screening of labgenerated butanol extract against AR-positive LNCaP and ARnegative PC3 cells
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Compound 1

Figure 37: In vitro prostate cancer cell screening of Compound
(1) against AR-positive LNCaP and AR-negative PC3 cells

Compound 2

Figure 38: In vitro prostate cancer cell screening of Compound
(2) against AR-positive LNCaP and AR-negative PC3 cells
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Figure 39: Ethyl acetate (bottom) fraction from 30% ethanol extract of
Iresine celosia overlaps strongly with the butanol partition (top)
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15 mL of Odyliresin Formulation

Lab-generated Formulation

• 16L 30% ethanol added to 2K aerial
I. celosia plant material
• 9L ethanolic extract recovered and
evaporated in vacuo to 4.5 mL

• Ethanol evaporated in vacuo to 10 mL

Liquid-liquid partition

Liquid-liquid partition

•
•
•
•
•

Added 10 mL n-hexanes
Shook vigorously and let settle for 10 min.
Collected water layer
Repeated above steps 3x
Repeated entire procedure with ethyl
acetate, and then n-butanol

•
•
•
•
•

Added 10 mL n-hexanes
Shook vigorously and let settle for 10 min.
Collected water layer
Repeated above steps 3x
Repeated entire procedure with ethyl
acetate, and then n-butanol
n-Butanol layer

n-Butanol layer

• Dried using in vacuo
• Reconstituted in 30% HPLC-grade

• Dried in vacuo
• Reconstituted in 30% HPLC-grade

methanol and DI water

methanol and DI water
HPLC-DAD

HPLC-DAD

Fig. 40: Procedure for the determination of compounds in labgenerated Iresine celosia extract and manufacturer’s
Odyliresin™ formulation
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Table 10: Characteristics of the compounds isolated from
the Iresine celosia lab formulation’s butanol extract (Labbu)
Compound Name
1
2
3
4
5
6
7
8
9
10
11

MW

Compound 1
241.29
Compound 2
225.29
Hydroxygalegine
143.19
Uracil
112.09
Adenine
135.13
3-indole-carboxyllic 161.16
acid
2‘deoxy-uridine
228.20
2‘deoxy-thymidine 242.23
2‘deoxy-5'-O-methyl- 242.23
uridine
4-methoxy-benzoic 152.15
acid (anisic acid)
Phenylacetamide
135.07

peak(s)
nm
212
212
210
256
210, 260
212, 282

Rt
(min)
17.7
25.4
19
21.5
5.6
30

210, 260
264
210, 260

8.3
11.8
14.8

260

23.3

212

30.2

Table 11: Calibration curve data for selected compounds
isolated from the Iresine celosia lab formulation’s butanol
extract (Lab-bu)

Compound
1
2
3
4
8
10

Rt
(min)
17.7
25.4
19
21.5
11.8
23.3

Slope (+SD)

r^2

LOD

LOQ

(mg/mL)

(mg/mL)

21.3 x 10^7 (+ 8)
4.4 x 10^7 (+ 1.7)
3.3 x 10^7
4.3 x 10^7
19.5 x 10^7
14 x 10^7

0.99
0.99
0.99
0.99
0.99
0.99

0.13
0.18

0.39
0.57
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Figure 41: Lab n-butanol (Lab-bu) extract at 212 nm

Figure 42: HPLC-UV chromatograms of Iresine celosia 30% ethanol
extracts (D, F) and their butanol partitions (A, B, C, E) at various
concentrations showing the presence of compounds (1-11)
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Lab-bu

1

2

3

Figure 43: Compounds (1), (2), (3) retention times
compared with Lab-bu formulation (50 mg/mL)
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Lab-bu

4

8

10

Figure 44: Compounds (4), (8), (10) retention times
compared with Lab-bu formulation (50 mg/mL)
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Fig. 45: Calibration Curves for Compound (1) at concentrations
0.0626 to 1.0 mg/mL

Fig. 46: Calibration Curves for Compound (2) at concentrations
0.0626 to 1 mg/mL
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Fig. 47: Calibration Curves for Compounds (3) at various
concentrations

Fig. 48: Calibration Curves for Compounds (4) at various
concentrations

155

Fig. 49: Calibration Curves for Compounds (8) at various
concentrations

Fig. 50: Calibration Curves for Compounds (10) at various
concentrations
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Fig. 51: Calibration curve for presence of Compound (1) in Lab-bu
formulation

Fig. 52: Calibration curve for presence of Compound (2) in Lab-bu
formulation
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Table 12: Calibration curve data for presence of Compound
(1) in Lab-bu formulation
Formulation
Conc.
25
50
75
150
100
500

C1 (mAU)
24,095,597
35,298,368
48,057,725
93,947,009
77,316,453
114,027,640

Compound Conc.
y = 213,227,870.70x +
31,411,604.31

0.018
0.078
0.293
0.215
0.387

STDEV
75,927
177,776
146,607
50,742

RSD
%
0.3
0.5
0.3
0.1

Table 13: Calibration curve data for presence of Compound
(2) in Lab-bu formulation

Formulation
Conc.
25
50
75
100
150
500

C2 (mAU)
15,861,869
22,053,873
36,997,866
47,774,367
71,661,551
108,202,498

Compound Conc.
y = 44,367,064.37x
+ 12,035,158.63

0.086
0.226
0.563
0.806
1.344
2.168
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STDEV
33,011
2,788,877
4,930,550
10,840,923
2,871,870

RSD
%
0.2
12.6
13.3
15.4
4

Fig. 53: Calibration curve for presence of Compound (3) in Lab-bu formulation
(single run)

Fig. 54: Calibration curve for presence of Compounds (4) in Lab-bu formulation
(single run)
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Fig. 55: Calibration curve for presence of Compound (8) in Lab-bu formulation
(single run)

Fig. 56: Calibration curve for presence of Compound (10) in Lab-bu formulation
(single run)
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Fig. 57: Calibration curve for presence of Compound (1)
in Odyli-bu formulation

Fig. 58: Calibration curve for presence of Compound (2)
in Odyli-bu formulation
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Table 14: Calibration curve data for presence of Compound
(3) in Lab-bu formulation
Conc.
25
50
75
100
150
500

C3
13,658,054
19,351,673
25,341,316
29,427,093
44,140,639
72,696,509

y = 32,909,431.43x +
34,707,557.30

0.287
1.154

STDEV
150,840
560,898
14,069
0
373,174
0

RSD%
1.1
2.9
0.001
0
0.8
0

Table 15: Calibration curve data for presence of Compound
(4) in Lab-bu formulation
Conc.
25
50
75
150

C4
6,264,923
11,605,373
17,337,917
33,534,116

y = 43,120,226.10x +
4,947,652.33

0.031
0.154
0.287
0.663

STDEV
20,434
81,082
204,982
192,108

RSD%
0.3
0.7
1.2
0.6

Table 16: Calibration curve data for presence of Compound
(8) in Lab-bu formulation
Conc.
25
50
75
150

C8
4,107,492
7,693,548
12,376,112
25,671,359

y = 194,620,399.2110x +
2,097,490.6430

0.010
0.029
0.053
0.12

STDEV
17,233
43,770
737,959
36,678

RSD%
0.4
0.6
6.0
0.1

Table 17: Calibration curve data for presence of Compound
(10) in Lab-bu formulation
Conc.
25
50
75
150

C10
6,198,365
11,484,942
17,255,272
34,207,895

y = 140,436,619.22x +
12,351,658.00

0.035
0.16
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STDEV
14,135
6,638
446,842
191,226

RSD%
0.2
0.1
2.6
0.6

Table 18: Calibration curve data for presence of Compound (1) in
Odyli-bu formulation
Formul.
Conc.

C1

75

Compound Conc.

STDEV

RSD
%

8,247,406

445,954

3.3

100

11,330,014

7,101

0.05

150

13,750,423

130,586

0.9

250

19,109,994

752,666

3.8

500

34,830,045

1,046,853

4.6

y = 44,367,064.37x +
12,035,158.63

0.016

Table 19: Calibration curve data for presence of Compound (2) in
Odyli-bu formulation
Formul.
Conc.

C2

50

13,671,820

75

Compound Conc.

STDEV

RSD
%

0.037

445,954

3.3

14,385,347

0.053

7,101

0.05

100

14,818,083

0.063

130,586

0.9

250

19,865,699

0.176

752,666

3.8

500

21,833,592

0.221

1,046,853

4.6

y = 44,367,064.37x +
12,035,158.63

163

Figure 60: Prediction of toxicity outcomes for the following
categories based on chemical structure
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Figure 61: Predicted sites of metabolism for Compound 1

Figure 62: Predicted metabolites for Compound 1
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Figure 63: Predicted sites of metabolism for Compound 2

Figure 64: Predicted metabolites for Compound 2
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Figure 65: Predicted metabolites for Compound 3
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